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ABSTRACT 
 
 
Obesity and diabetes are the most prevalent metabolic disorders. It is 
estimated that more than 86% of US adults would be overweight or obese 
and more than 50% obese by the year 2030.  Non Alcoholic Fatty Liver 
Disease (NAFLD) has also been referred to as hepatic manifestation of 
insulin resistance.   NAFLD or steatosis is defined as lipid accumulation 
exceeding 5% by weight in hepatocytes in the absence of substantial 
alcohol intake.  The prevalence of NAFLD is estimated to be between 17% 
and 40% of the world population, known to afflict obese and normal weight 
persons and children as well.  Epidemiological and clinical studies 
demonstrate changed pharmacokinetic and –dynamic parameters of drugs 
and environmental toxicants in models of NAFLD and cause drug induced 
liver injury (DILI) which can be attributed to altered expression of Phase I, 
Phase II drug metabolizing enzymes and drug transporter expression in 
human and rodent models of NAFLD.  NAFLD also causes propogation of 
insulin resistance complicating metabolic syndrome.  Due to its increasing 
prevalence throughout the world, understanding mechanisms and 
consequences of NAFLD and identifying novel targets to reverse this 
condition are of increasing clinical relevance. 
Nuclear factor-E2 related factor 2 (Nrf2) belongs to leucine zipper based 
loop-helix-loop family of transcription factors which plays an important role 
in activation of a battery of antioxidant genes, thus protecting the cells from 
  
oxidative stress which is either causality or a consequence that aggravates 
a number of disorders, an important condition being NAFLD.  Nrf2 is 
sequestered in the cytoplasm via sulfhydryl based interactions with Kelch 
like ECH-associated protein 1 (Keap1); oxidative stress disrupts these 
interactions and phosphorylation based changes in Nrf2 protein aid its 
translocation into the nucleus where it binds to antioxidant response 
element (ARE) and initiates transcription of the antioxidant gene battery 
which includes but not limited to NAD(P)H:quinine oxidoreductase 1 
(NQO1), hemoxygenase (HO1), glutamine cysteine ligase catalytic and 
regulatory subunit (GCLC and GCLM).  Hepatic clearance is a predominant 
mechanism for excretion of chemicals, such as hormones and drugs.  
Several families of transporters localized to sinusoidal and canalicular 
membrane of hepatocytes drive bile flow and biliary excretion.  Nrf2 also 
regulates expression of ATP-binding cassette (ABC) superfamily of 
membrane proteins, efflux organic anions into bile (e.g. Abcc2) and from 
hepatocytes into blood (e.g. Abcc3 and 4), which contribute to hepatic 
clearance of various endogenous and exogenous chemicals.   
Diet (caloric restriction, CR) and exercise are the recommended therapeutic 
intervention to treat NAFLD and reverse hepatic fat accumulation.  
Beneficial effects of CR are attributed to activation of Sirtuin 1, a NAD (+)-
dependent protein deacetylase which activates gluconeogenic and fatty 
acid oxidation genes expression via coactivator; Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha.  The important regulatory 
  
roles of SIRT1 in both lipid and glucose metabolism make it an important 
molecule in hepatic mechanisms in development of steatosis. 
Resveratrol, an antioxidant compound and a potent Sirt1 activator also 
activates Nrf2 in certain in vitro models as determined by an increase in the 
expression of prototypical Nrf2 target genes.  Additionally, Nrf2 has been 
implicated in protection against development of cancer in mice undergoing 
CR.  Ability of CR mimetics or Sirt1 activators to activate Nrf2-Keap1 
pathway and scant but significant evidence of Nrf2 in nutrient regulation 
demand an indepth analysis of the Nrf2-Keap1 pathway in the nutrient 
deprived conditions.     
A possible role of Nrf2 in adipogenesis, adipocyte differentiation as well as 
glucose tolerance has been suggested in mouse models, however, very 
little is known about Nrf2 signaling pathway in nutrient deprived states.    
Very little is known about effect of nutritional status on biliary clearance 
mechanisms or bile flow.   
 
The purpose of study performed in MANUSCRIPT I is to elucidate the effect 
of fasting pathways on Nrf2-Keap1/ARE pathway.  Few studies exist 
regarding how fasting affects transporter or the nuclear receptor-regulated 
pathways which regulation expression.  Fasting effects on the Nrf2-Keap1 
signaling pathway, which is responsive to oxidative stress and altered redox 
status have not been elucidated.  The observations presented in this study 
prove that 1) fasting increases Abcc expression through Nrf2- and Sirt1-
  
dependent mechanisms, 2) cAMP/PKA activators increase ARE activation 
via Nrf2- and Sirt1-dependent mechanisms in vitro, 3) Nrf2 expression is 
co-ordinately regulated with Pgc-1α and Sirt1 expression and 4) 
obesity/steatosis diminishes fasting-mediated Abcc induction.   
In summary, MANUSCRIPT-I demonstrates that fasting and PKA activators 
increase mouse Abcc2-4 expression in liver by Nrf2- and Sirt1-related 
mechanisms in mouse liver and hepatocytes.  Additionally, 8-Br-cAMP and 
PKA activating compounds increase Nrf2 target gene and ABCC2-4 mRNA 
expression in human hepatocytes.  Our data illustrate an undescribed role 
for Nrf2 as a “fasting” responsive transcription factor that is activated via 
cAMP/PKA-Sirt1 upstream mechanisms. 
CR alters activity and expression of various biotransformation enzymes 
such as Sult2a1, Cyp2b10, Ugt1a1, CYp4a14 in liver.   However, to our 
knowledge, no studies have shown how CR actually affects drug 
transporter expression in livers of obese mice, which have hepatic steatosis 
and better mimic the population most likely to undergo intervention.  The 
purpose of study performed in MANUSCRIPT II hypothesized that CR 
would reverse the NR and drug transporter expression changes previously 
observed in obesity-induced hepatic steatosis.  Given the well-defined 
association of Nrf2 with Abcc transporter induction, emphasis was placed 
on the Nrf2 pathway, but other NRs that have been described to regulate 
transporter expression were also evaluated.  Our data herein illustrate that 
CR differentially regulates NR, biotransformation enzyme, and transporter 
  
expression in livers from C57Bl/6 (WT) and Lepob/ob (OB) mice.  
Furthermore, AMPK and Sirt1 activators differentially modulated transporter 
and NR expression in lean and steatotic hepatocytes. 
To summarize, MANUSCRIPT II demonstrates that activation of CR 
pathways can only partly reverse the changes in drug metabolizing enzyme 
and transporter expression occurring due to fat deposition in the liver.  
Leptin appears to play an important role in upstream regulation of pathways 
that relay CR signals to ultimately change DME and DT expression.  The 
above observations also indicate that the inability of CR to reverse certain 
DME and DT changes may indicate towards altered disposition and 
pharmacokinetics of metabolites and xenobiotics.  Data also shows that CR 
decreases the expression and activity of Nrf2-ARE regulatory pathway and 
target gene expression. 
Small non-coding RNAs, microRNAs have been recently demonstrated to 
provide an additional layer of regulatory control in development, 
homeostasis and pathology.  miRNA expression and regulation are being 
explored in detail as potential targets and possible biomarkers in various 
diseases, specifically metabolic syndrome and cancer.  Various miRNAs 
such as miR34a, miR122, miR370, miR221, miR33a, let-7 have been 
proven to be important regulators of fatty acid oxidation and lipid synthesis 
regulators such as Sirt1, Pgc-1α, Srebp1c, Lxr.  In MANUSCRIPT III we 
demonstrate differential susceptibility of a mouse model, constitutively 
  
overexpressing Nrf2 (Keap1-KD mice) to CR.  We attribute these changes 
to novel changes in the miRNA regulatory circuit.     
 
 
.  We demonstrate that the enhanced susceptibility to CR in Nrf2 
overexpressing mice could be partly associated with differential changes in 
miRNA expression such as miR34a, miR370, miR122 and miR144, 
especially those known to be involved in regulation of lipogenic as well as 
fatty acid oxidation genes. 
In summary, the studies presented herein demonstrate Nrf2-ARE pathway 
is a nutrient sensitive pathway that is: (a) activated upon fasting via Sirt1-
Pgc-1α dependent mechanisms, (b) negatively regulated upon CR and 
AMPK pathway, (c) plays a role in development of obesity, and (d) 
regulates expression of miRNA regulatory circuit thereby changing 
susceptibility to weight loss and fatty acid metabolism, (e) is a potential 
target to alleviate metabolic syndrome. 
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PREFACE 
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‘Guidelines for the Format of Theses and Dissertations’ standards for 
Manuscript format. This dissertation consists of five manuscripts that have 
been combined to satisfy the requirements of the department of Biomedical 
and Pharmaceutical Sciences, College of Pharmacy, University of Rhode 
Island. 
MANUSCRIPT I: Fasting Induces Nuclear Factor E2-Related Factor 2 
and ATP-Binding Cassette Transporters via Protein Kinase A and 
Sirtuin-1 in Mouse and Human Models.  
This manuscript has been prepared for submission to ‘Antioxidant Redox 
Signaling’ as an original research communication. 
MANUSCRIPT II: Effect of Caloric Restriction and AMPK Activation on 
Nuclear Receptor, Biotransformation Enzyme, and Transporter 
Expression in Livers of Lean and Obese mice. 
This manuscript has been prepared for submission to ‘Journal of 
Pharmacology and Experimental Therapeutics’ as an original research 
communication. 
MANUSCRIPT III: Differential expression of micro-RNAs regulating 
lipid metabolic genes enhances susceptibility to caloric restriction in 
models of constitutive Nrf2 overexpression. 
This manuscript has been prepared for submission to ‘Pharmaceutical 
Research’ as an original research communication. 
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Abstract 
Aim: The purpose of this study was to determine how fasting modulates 
Nrf2 activity and ABCC expression in liver, with specific focus on cAMP-
protein kinase A (PKA) and Sirtuin-1 (Sirt1) dependent mechanisms.   ATP-
binding Cassette (ABC) transport proteins (ABCC2-4) are essential for 
chemical elimination from hepatocytes and biliary excretion.  Nuclear factor-
E2 related-factor 2 (Nrf2) is a transcription factor that mediates ABCC 
induction in response to chemical inducers and liver injury.  However, a role 
for Nrf2 in the regulation of transporter expression in non-chemical models 
of liver perturbation is largely undescribed.  
Results: Here we show that fasting increased Nrf2 target gene expression 
through Nrf2- and Sirt1 –dependent mechanisms. In intact mouse liver, 
fasting induces Nrf2 target gene expression by at least 1.5 to 5 fold. In 
mouse and human hepatocytes, treatment with 8-Br-cAMP, a cAMP 
analogue, increased Nrf2 target gene expression and antioxidant response 
element activity, which was decreased by the PKA inhibitor, H-89. 
Moreover, fasting induced Nrf2 target gene expression was abolished in 
liver and hepatocytes of Sirt1 liver-specific null mice and Nrf2-null mice.  
Additionally, leptin deficient (OB) obese mice were more resistant to fasting 
effects on Nrf2 target gene induction compared to lean mice. 
Innovation: Nrf2 activation by oxidative stress is well described, yet the 
influence of basic metabolic processes on Nrf2 activation remain largely 
undescribed. 
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 Conclusion: The current data points toward a novel role of nutrient status in 
regulation of Nrf2 activity and the antioxidant response, and indicates that 
cAMP/PKA and Sirt1 are upstream regulators for fasting-induced activation 
of the Nrf2-ARE pathway.  
 1 
 
INTRODUCTION 
Members of the ATP-binding cassette (ABC) superfamily efflux organic 
anions from hepatocytes into bile (e.g. Abcc2) and blood (e.g. Abcc3 and 
4).  Increased Abcc2 expression increases biliary excretion of organic anion 
(e.g. DBSP), whereas increased Abcc3 expression reverses vectorial 
excretion of glucuronide conjugates into blood (29).  Genetic and 
pharmacological Nuclear factor-E2 related factor 2 (Nrf2) activation can 
upregulate Abcc2-4 expression in liver (29,38). 
 
Nrf2 belongs to the basic leucine zipper (loop-helix-loop) family of 
transcription factors, and is tethered in the cytoplasm as a complex with 
Kelch like associated protein-1 (Keap1) as reviewed by Kobayashi et al. 
(31) .  Upon activation, Nrf2 translocates to nucleus and activates gene 
transcription by binding to Antioxidant Response Element (ARE).  Nrf2 is 
responsive to cellular redox status alterations (41) and is largely described 
to mediate induction of xenobiotic metabolism and cytoprotection genes, 
such as Nadph:quinone oxidoreductase (Nqo1) and glutamate-cysteine 
ligase, catalytic subunit (Gclc), in response to oxidative stress and change 
in cellular redox status (27). 
 
Nutrient homeostasis in liver relies on redox status.  During fasting, 
decreased glucose and increased pyruvate concentrations increase the 
NAD+/ NADH ratio, initiating a cascade of events that activate 
 2 
 
gluconeogenesis (46).  Fasting increases glucagon, which increases 
intracellular 3'-5'-cyclic adenosine monophosphate (cAMP) content (33), 
activates protein kinase A (PKA), and modulates transcription of multiple 
genes in liver that maintain glucose homeostasis, metabolism, and 
transport (9).  cAMP/PKA cascade activates downstream expression of 
gluconeogenic genes, restoring blood glucose levels to normal (5).  Short-
term fasting induces gluconeogenesis via mTOR/TORC2 pathway which is 
inhibited during longer fasting intervals by Sirtuin1 (NAD-dependent 
deacetylase, Sirt1) switching to the use of free fatty acids as precursors for 
glucose production via deacetylation and activation of PPAR gamma 
coactivator alpha (Pgc-1α) and Forkhead Box O1 (Foxo1).  (20,36,46).   
 
Along with gluconeogenic genes, fasting induces transcription of some 
genes involved in biotransformation (e.g. Cyp2b10, CYP2C11, CYP2E1, 
CYP2B1/2) and transport (e.g. Slco1b2) in coordination with nuclear 
receptors (6,10).  However, little is known about effect of nutritional status 
on biliary clearance mechanisms or bile flow.  Few studies exist regarding 
how fasting affects transporter or the nuclear receptor-regulated pathways 
which regulation expression.  Fasting effects on the Nrf2-Keap1 signaling 
pathway, which is responsive to oxidative stress and altered redox status 
have not been elucidated.  Some evidence suggests a possible role for Nrf2 
in lipid and glucose homeostasis (3,43), very little is known about how 
fasting affects the Nrf2-Keap1 pathway. To date, no studies have 
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addressed how Sirt1 regulates Nrf2 activity and subsequent gene 
expression in vivo.  
 
The purpose of this study was to identify whether 1) fasting increases Abcc 
expression through Nrf2- and Sirt1-dependent mechanisms, 2) cAMP/PKA 
activators increase ARE activation via Nrf2- and Sirt1-dependent 
mechanisms in vitro, and 3) how obesity impacts fasting-mediated Abcc 
induction.   The current study determines whether fasting and 
pharmacological activation of the fasting response pathway increases Nrf2 
activity and upregulates Abcc2-4 expression through cAMP/PKA-Sirt1-
dependent mechanisms.  Data herein present an undescribed role for Nrf2 
as a “nutrient sensitive” responsive transcription factor that is regulated via 
Sirt1-dependent mechanisms in vivo, and illustrate that in obesity, hepatic 
clearance mechanisms are differentially affected by fasting. 
 
 
EXPERIMENTAL PROCEDURES 
Animals and treatments. Adult male C57Bl/6 and OB mice (n=8/group), 
Nrf2-null (n=6/ group) (24) and ARE-hPAP reporter mice (n=3/ group) (26) 
were fed Harlan Teklad LM-485 Mouse/Rat Sterilizable Diet (Harlan 
Laboratories, IN,USA) ad libitum or were food withheld for 24 hrs.  Adult 
male Sirt1-LKO (44) and Sirt-WT mice (n=3) were fed standard chow ad 
libitum or were food deprived (fasted) for 18 hrs.   Blood and livers were 
 4 
 
collected between 9-11 am for all individual fasting experiments.   Livers 
from Sirt1 overexpressing (Sirt1-OE) fed or fasted mice were obtained from 
J. Rodgers and P.Puigserver from a previously described study (47).  
Serum glucose (Cayman Chemicals, Ann Arbor, MI), triglyceride (TG) 
(Pointe scientific, MI, USA) and free fatty acid (NEFA) concentrations 
(Wako diagnostics, VA), hepatic and serum cAMP (Cell Signaling 
Technologies, Danvers, MA, USA), serum bile acids (Bioquant Kits, San 
Diego, CA, USA) were determined according to manufacturer’s instructions. 
 
Determination of biliary excretion of disulfobromophthalein (DBSP): 
Adult, male, C57Bl/6 (n=5 per group) were fed standard chow ad libitum or 
were food withheld for 18 hrs.  DBSP, purchased from SERB Laboratories 
(Paris, France) was injected i.p. (150 μmol/kg/5ml) and 45 minutes after 
injection gallbladders were collected.  Bile DBSP content (μmol/ μl bile/kg 
body weight) was determined spectrophotometrically at 580 nm after 
alkalinization with 0.1N NaOH.  
  
Cell Lines and Treatments. Huh-7 cells were treated with 0.5-2.0 mM 8-
Bromoadenosine-3', 5’-Cyclic Adenosine Monophosphate (8-Br-cAMP) 
(Sigma Aldrich, St.Louis, MO, USA) or media alone for 24 hrs.  Huh-7 cells 
were cultured to 85% confluence and transiently transfected with an ARE–
luciferase (0.1 µg) (14) and pRL-CMV (0.01 µg) reporter constructs using 
lipofectamine-plus reagent (Invitrogen, CA, USA).  24 hrs after transfection, 
 5 
 
cells were treated with 0.1mM or 1.0mM 8-Br-cAMP for 24 hrs (15)  .  
Luciferase activity was measured using a Dual Luciferase Assay (Promega 
Corp., MD, USA), and Firefly Luciferase Relative Light Units (RLUs) were 
normalized to Renilla Luciferase RLUs.   
 
Plasmid transfections and endogenous gene expression analysis.  All 
plasmids used were obtained from Addgene plasmid repository 
(Cambridge, MA).  Huh-7 cells were transiently transfected with (0.5-1.0µg) 
Flag-Pgc-1α, 75ng Flag-Nrf2 and 50ng Myc-Sirt1 expression plasmids or 
(50-100ng) Myc-Sirt1, 75ng Flag-Nrf2 and 0.5µg Flag-Pgc-1α expression 
plasmids using Lipofectamine LTX-plus reagent (Invitrogen, CA, USA) for 
24 hrs.  Cells were then treated with 1.0mM 8-Br-cAMP for 24 hrs.  Nrf2 
and Pgc-1α mRNA expression was measured using real time quantitative 
PCR, with expression being normalized to 18S rRNA expression. 
 
Immunoprecipitation (IP) Assay. Huh-7 cells were cultured in 6 cm dishes 
and transiently transfected with 3.0µg Flag-tagged Nrf2, with or without 
0.75µg cMyc-tagged Sirt1 plasmid for 24 hrs using Lipofectamine LTX-plus 
reagent (Invitrogen, CA, USA).  After 24 hrs, cells were treated with 1.0mM 
8-Br-cAMP for 45 mins and lysed with buffer (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.05% NP-40).  1mg protein lysate was incubated with Anti-
FlagM2 magnetic beads (Sigma Aldrich, St.Louis, MO) overnight in lysis 
buffer.  After incubation, beads were washed with Tris-Buffered Saline, pH 
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7.4, mixture boiled with SDS samples buffer, and immunoprecipitates were 
separated on a 10% SDS-PAGE followed by immunoblotting against Pgc-
1α (Abcam, Cambridge, MA), FlagM2 and c-myc (Sigma Aldrich, St.Louis, 
MO).  
 
Primary hepatocyte isolation, culture, and treatment. Primary mouse 
hepatocytes were obtained from adult C57Bl/6, ARE-hPAP and SirtLKO 
mice as described previously (54) .  Primary human hepatocytes 
(Cellzdirect™, NC, USA) were maintained in William’s E Media 
supplemented with Cellzdirect ™ recommended supplements.  Hepatocytes 
were treated with DMSO vehicle or 1.0mM 8-Br-cAMP dissolved in DMSO 
for 24 hrs. 
 
mRNA Quantification. Total RNA was isolated from tissue and cells using 
TRIzol reagent (Invitrogen, CA, USA).  mRNA expression was quantified by 
Branched DNA signal amplification assay or real time quantitative PCR, 
with expression being normalized to 18S rRNA expression.  At the end of 
treatment, primary human hepatocytes were lysed with Lysis Mixture™ 
(Panomics Inc.,Freemont, CA) according to manufacturer’s protocol and 
stored at -80°C until analysis.  mRNA expression was measured using 
Quantigene® Discover Kit (Panomics Inc.,Freemont, CA).  Target gene 
expression was normalized to ß-actin expression. 
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Western blot and immunohistochemistry. Proteins were 
electrophoretically separated by SDS-PAGE and transferred to PVDF 
membrane.  Membranes were blocked with 5% Non-fat dry milk in 
phosphate-buffered saline with 0.05% Tween-20 overnight, and then 
incubated with appropriate concentrations of primary and secondary 
antibodies.  The blots were incubated in ECL-Plus western blot detection 
reagent.  Bands were visualized using autoradiography film and quantified 
using Image Quant Software (GE Healthcare and Life Sciences, N J, USA).  
Details are described in (39) and Abcc2 staining immunostaining of liver 
sections was performed as described (4). 
 
Nrf2 binding Assay. Nuclear extracts were isolated from livers using a TF 
Procarta nuclear extraction kit (Panomics Inc, Freemont,CA, USA) and 
protein concentrations were measured by a BCA protein assay (Pierce, 
Rockford, IL, USA).  Nrf2 binding to a prototypical ARE consensus 
sequence was quantified using a Procarta TF custom array (Affymetrix, 
Santa Clara,CA) according to manufacturer’s instructions.  Data was 
acquired by a Luminex Bio-plexTM 200 Array reader with Luminex 100 X-
MAP technology, and data were acquired using Bio-Plex Data Manager 
Software Version 5.0 (Bio-Rad Laboratories, Hercules, CA, USA).  All data 
was normalized to TFIID binding activity. 
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NAD+/NADH Assay.   Tissue NAD+/NADH was measured using 
NAD/NADH assay kit (BioVision Inc., CA,USA) according to manufacturer’s 
protocol. 
 
Statistics. Statistical significance of differences was determined by 
Duncan’s factorial ANOVA test.  P<0.05 was considered statistically 
significant. Groups without a common letter are significantly different. 
 
 
RESULTS 
Fasting increases Abcc2-4 expression in liver and hepatocytes.    First, 
it was determined whether fasting modulates biliary clearance via induction 
of Abcc transporters expression and activity. Fasting increased excretion of 
DBSP, a prototypical organic anion that undergoes biliary excretion via 
Abcc2 (29), into gallbladder bile by ~3 fold compared to fed mice (Fig. 1A). 
Fasting correspondingly increased liver Abcc2-4 mRNA levels (Fig. 1B) and 
Abcc2-4 protein expression (Fig. 1C) compared to mice fed ad libitum.  
Abcc induction in liver was time dependent, and as length of fasting 
increased, induction declined (Supp. Fig. 2 and 3).  8-Br-cAMP, a cAMP 
analogue that activates cAMP/PKA pathway, increased expression of 
Abcc2-4 by 6, 1.75 and 1.5 fold in primary mouse hepatocytes (Fig.1D).  
Additionally, 8-Br-cAMP induced ABCC2-4 expression by 5, 2, and 1.25 
fold, in Huh-7 hepatocarcinoma cells (Fig. 1E); indicating that fasting 
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induced activation of Nrf2 was conserved in human-derived cells. In line 
with these data, several upstream activators of fasting pathway, glucagon, 
epinephrine, and 8-Br-cAMP, increased ABCC2-4 expression in primary 
human hepatocytes (Fig. 1F).  
 
Nqo1 is considered to be a prototypical Nrf2 target gene in mouse and 
human (30).  As shown in Figure 2A, fasting not only increased mRNA 
levels of Nqo1, but also Nrf2 itself in mouse livers by at least 1.5 fold over 
fed controls (Fig. 2A).  Fasting correspondingly increased Nqo1 protein 
expression by ~3 fold over fed controls (Fig. 2B). Moreover, 8-Br-cAMP, a 
PKA activator, increased Nqo1 expression by 2 fold in primary mouse 
hepatocytes (Fig. 2C).  Additionally, PKA activators increased NQO1 
expression in primary human hepatocytes (Fig. 2D).   Similarly, Huh-7 cells 
treated with 8-Br-cAMP demonstrated a 2 fold increase in NQO1 mRNA 
expression accompanied by increased NQO1 protein expression in cytosols 
of these cells (Fig. 2E).  
 
To further explore the molecular mechanism underlying the fasting induced 
activation of Nqo1 and ABCC2-4, we examined subcellular localization of 
Nrf2 before and after 8-Br-cAMP treatment. As shown in Figure 2D, 
increase in ABCC2-4 and NQO1 expression was preceded by increased 
nuclear accumulation of Nrf2 at 1 and 3 hrs post treatment in mouse 
hepatocytes along with increased cytosolic Nqo1 expression (Fig. 2D), as 
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well as by increased Nrf2 binding in Huh-7 cells (Supp. Fig. 4).  The 
observations indicate that activation of fasting pathways induces Nrf2, 
Nqo1, Abcc2-4 mRNA and protein expression in mouse and human in vitro 
and in vivo models. 
 
Fasting induces Nrf2 activation and Abcc2-4, and Nqo1 expression in 
WT in part through Nrf2-dependent mechanisms. To determine whether 
fasting induces expression of Nrf2 target genes through Nrf2 dependant 
mechanisms, relative Nqo1 and Abcc expression in WT and Nrf2-null fasted 
mice was quantified.  Fasting increased Nqo1, Abcc2-4 expression at 24 
hrs in Nrf2 WT mice, whereas expression in livers of Nrf2-null mice was 
significantly lower (Fig. 3A).  The relative mRNA fold increase in Nqo1 
mRNA was higher than Abcc2-4, which is consistent with a previous 
observation (2,55).  Fasting also increased Abcc2 protein staining in livers 
of C57Bl/6 mice, but not in livers of Nrf2 null mice (Fig. 3B).  Further, fasting 
increased Abcc2, Abcc3, Nqo1 protein expression (Fig. 3C).  This increase 
was accompanied by an increased Nrf2 binding to consensus ARE 
sequence in liver nuclear extracts from Nrf2 WT fasted mice (Fig. 3D). 
To identify whether changes in mRNA and protein expression of Abccs 
during fasting contributed to phenotypic changes in metabolites and 
substrates, we quantified serum and liver cAMP in Nrf2 WT and Nrf2 null 
fed and fasted mice because cAMP is a described substrate for Abcc4 
(11,34).  Fasting increased serum cAMP levels in WT mice by ~1.77 fold 
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whereas they remained unchanged in sera of Nrf2 null mice, whereas liver 
cAMP levels in Nrf2 WT mice decreased by 48% upon 24 hr fasting, but 
remained unchanged in the Nrf2 null mice (Fig. 3D), which corresponds to 
the observed lack of Abcc4 induction (Fig. 3A).       
 
To further test the possibility that Nrf2 induces expression of its targets 
through ARE, ARE-hPAP reporter transgenic mice possessing a human 
alkaline phosphatase reporter downstream of ARE consensus sequence 
(26) were fasted hPAP mRNA expression was determined.  Fasting 
increased hPAP and Nqo1 mRNA expression in livers of ARE-hPAP mice 
by 8 and 5 fold compared to fed controls (Fig. 3F).  hPAP mRNA 
expression was somewhat more inducible than Nqo1 mRNA expression, 
which is consistent to a previous publication (53).   8-Br-cAMP increased 
hPAP mRNA expression by about 2.5 fold in primary mouse hepatocytes 
isolated from ARE-hPAP mice (Fig. 3G).  These results indicate that fasting 
induces Nrf2, Nqo1 and Abcc2-4 in part through Nrf2.  Other transcription 
factors such as CAR, PPARα also regulate expression of Abcc2-4 (15).  
However, Nrf2-null mice exhibited dampened induction of Abcc2-4 
indicating that fasting induction of Abcc2-4 occurs via some Nrf2 dependent 
mechanisms.   
 
8-Br-cAMP activates cAMP/PKA pathway upstream of Nrf2-ARE 
activation.  To identify a connection between cAMP/PKA signaling pathway 
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and Nrf2 activation, induction of ARE-driven luciferase reporter was 
analyzed in Huh7 cells treated with 8-Br-cAMP, glucagon and epinephrine.  
As shown in Fig. 4A and Supp. Fig. 5, all three treatments increased ARE-
driven luciferase activity by about 1.5-2.5 fold.  Primary ARE-hPAP mouse 
hepatocytes treated with 8-Br-cAMP showed increased hPAP expression, 
which was muted upon treatment with H89 (Fig. 4B).  8-Br-cAMP treatment 
increased Nrf2, Nqo1, Abcc2 and 4 mRNA expression in primary 
hepatocytes isolated from Nrf2-WT, but not in Nrf2-null hepatocytes (Fig. 
4C and 4D).  Induction of Nrf2, Nqo1, Abcc2, and Abcc4 expression by 8-
Br-cAMP was blunted by H89 in Nrf2-WT hepatocytes, but not in Nrf2-null 
hepatocytes (Fig. 4C and 4D).   
Induction of NAD+/NADH is one mechanism that activates Sirt1.  Liver 
NAD+/NADH levels were decreased by ~50% in Nrf2-null compared with 
Nrf2 WT mice (Fig. 4E).  Fasting resulted in a greater fold increase in liver 
NAD+/NADH ratio in Nrf2-null mice as compared to the WT mice (Fig. 4E), 
but as seen from Fig. 3D, Nrf2 null mice did not demonstrate the changes in 
cAMP levels as seen in the Nrf2 WT mice.  Lack of Nrf2 did not affect Pgc-
1α and Pepck expression in these mice (Supp. Fig. 6), indicating that 
fasting induced expression of gluconeogenic genes is not Nrf2 dependant.  
However, even though upstream pathways of fasting were activated in Nrf2 
null mice, Abcc2-4 and Nqo1 expression was muted indicating that 
induction of these target genes occurs via Nrf2 dependant mechanisms. 
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In primary mouse hepatocytes AMPK activators AICAR, MET and NAD+ 
failed to induce Nrf2 and Nqo1, further suggesting a role for cAMP/PKA 
instead of the AMPK pathway (Fig. 4F).  Total AMPKα and p-AMPKα levels 
decreased in livers of WT mice, but were unchanged in Nrf2-null livers, 
further suggesting that AMPK activation was not upstream to Nrf2 activation 
(Fig. 4G).  These observations indicate that cAMP/PKA induces expression 
of ARE-containing genes via Nrf2-dependent mechanisms.      
 
Fasting induced Abcc2-4 and Nrf2-target gene expression is Sirt1-
dependent in vivo.  In addition to cAMP/PKA signaling pathway, previous 
studies have indicated that Sirt1 is a critical mediator of fasting-induced 
expression and activation of Pgc1-α (47), as well as other fasting 
physiologies such as gluconeogenesis, fatty acid oxidation, and 
ketogenesis (7).  To test whether Sirt1 plays a role in fasting induced 
activation of Nrf2, liver-specific Sirt1-null mice were fasted and expression 
of Abcc2-4 determined.  Absence of functional Sirt1 in liver minimally 
affected basal expression of genes measured (Fig. 5A).  Upon fasting, Nrf2 
and Abcc2-4 mRNA expression were induced in livers of control mice, but 
not in Sirt1LKO mice (Fig. 5A).  Fasting increased Nqo1 expression to a 
similar degree in Sirt1-WT and Sirt1-LKO mice.  Conversely, adenoviral 
over-expression of Sirt1 enhanced fasting induced Nrf2 and Abcc2-4 
expression (Fig. 5B).   
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Nrf2 expression increases co-ordinately with increasing Sirt1 and Pgc-
1α in vitro. 
In order to identify whether the Sirt1-Pgc-1α cascade acts upstream of the 
Nrf2-ARE pathway during fasting, Nrf2 and Pgc-1α mRNA expression was 
quantified in Huh7 cells transfected with either constant or varying  amounts 
of Nrf2 ,Sirt1 and Pgc-1α.  As depicted in Fig. 6C and 6D, Nrf2 expression 
was coordinately regulated with Pgc-1α.  Nrf2 expression increased by 5-7 
fold (Fig. 6C) and 1.5-2 fold (Fig. 6D) with increasing concentration of Sirt1 
and Pgc-1α expression plasmid, respectively.  8-Br-cAMP increases this 
fold induction of Nrf2 further in both cases (Fig. 6C and 6D).  Thus, Sirt1-
Pgc-1α cascade potentially acts upstream of Nrf2-ARE pathway, increasing 
transcription of Nrf2 and possibly its activity.  IP assays were performed on 
Huh7 cells transfected with Flag-Nrf2/cMyc-Sirt1 or Flag-Nrf2 only and 
treated with 8-Br-cAMP to determine whether Sirt1 or Pgc-1α possibly could 
act as transcriptional activators.  8-Br-cAMP induced cMyc protein 
expression indicating and induction of Sirt1 protein (Supp. Fig. 7) as well as 
FlagM2 protein in the immunoprecipitate indicating an increase in Nrf2 
expression (Fig. 6F)   Immunoprecipitation of Flag- tag by Anti-Flag M2 
antibody resulted in coimmunoprecipitation of endogenous Pgc-1α along 
with Flag-Nrf2 (Fig. 6F) indicating that Pgc-1α could be a coactivator of 
Nrf2-ARE transcriptional pathway.  It is also interesting to observe that this 
coimmunoprecipitation was barely detectable in cells which were not 
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transfected with Sirt1 expression plasmid (Fig. 6F).  Sirt1 (c-Myc antibody) 
is also co-immunoprecipitated along with Nrf2 (Fig.6F).   
Above observations indicate that Pgc-1α acts as a positive upregulator of 
Nrf2 expression and Nrf2 transcriptional pathway with activity of Pgc-1α 
partly dependent on presence of Sirt1.   
 
Effect of fasting in obese mice.  Leptin-deficient obese mice (Lepob/ob, 
OB) were fasted to determine whether similar fasting induction of Nrf2 
activity and Abcc2-4 upregulation occurs.  A differential fasting response 
was observed in OBs compared to C57BL/6 mice with regard to serum 
chemistry (Supp. Table 1).  In fed mice, hepatic mRNA Abcc2-4 expression 
was elevated in OB mice, consistent with a previous report (13).  Fasting 
did not increase Abcc2 and 3 in livers from OB mice, and Abcc4 mRNA 
expression was decreased compared to fed OB mice (Fig. 7). In general, 
obesity blunted fold induction of Abcc2-4, Nrf2 and Nqo1 as the observed 
fold induction was lower in obese mouse livers.  
 
 
DISCUSSION      
Studies herein demonstrate that fasting upregulates Nrf2 activity and 
increases mouse and human ABCC2-4 expression in liver via cAMP/PKA-
Sirt1 dependant mechanisms.  Hepatic transport mechanisms are integral 
to liver function to maintain systemic hormone and second messenger 
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levels.  There are only a handful of published observations that document 
effects of fasting on hepatic clearance mechanisms.   
 
Nrf2 is best described for regulating xenobiotic detoxification and clearance 
mechanisms, such as glutathione synthesis and conjugation enzymes, 
Phase-II biotransformation enzymes, and Abcc transporters (30).  As an 
oxidative stress sensor; it is activated by reactive oxygen species, as well 
as antioxidants.  A majority of studies demonstrate a classical function of 
Nrf2 in mediating cytoprotective response in response to xenobiotic insult or 
disease, but few identify whether Nrf2 participates in basic metabolic 
functions.  Herein, we demonstrate that fasting response upregulates Nrf2-
ARE activation, subsequent target gene mRNA, and protein expression, 
along with corresponding increased Nrf2-ARE binding in both mouse and 
human models.   
 
It is interesting to consider why Nrf2 activation and hepatic clearance 
mechanisms are upregulated during food deprivation.  Fasting causes a 
metabolism shift from lipid storage to lipid oxidation for energy generation, 
resulting in fat mobilization from adipose to liver, and consequently 
increasing lipid peroxidation products (1).  Lipid breakdown in fasting 
preferentially increases arachidonic acid, stearic acid and docosahexanoic 
acid, which are probable substrates for Abcc3 (12,32).   A consequence of 
fasting is hepatic lipid accumulation and break down, as well as, increased 
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bilirubin, bile acids, and cyclic nucleotides, which are all substrates for 
Abcc2-4.  Fasting increases hepatic cAMP (33), cGMP (37), bilirubin (22), 
UGT expression (35), lipid peroxidation products, bile acids (45), bile flow 
(49), and forms glutathione conjugates, which depletes cellular glutathione 
(1) .   Fig. 8 illustrates how fasting may increase Nrf2 and the ARE to 
enhance hepatic clearance mechanisms of endogenous metabolites 
through Abcc2-4 upregulation.  For example, mouse and human ABCC2 
are known to be high affinity transporters for bilirubin-glucuronide and 
contribute to bilirubin excretion to bile (25).  Fasting increases bilirubin 
glucuronidation (51) and Abcc2 induction could be in response to increase 
bilirubin clearance.  Second, as ABCC2-4 contribute to bile acid efflux from 
hepatocytes, induction might aid in decreasing the increased bile acid load 
that occurs with fasting. Third, cAMP and cGMP are substrates for Abcc4 
(52), and our data herein illustrate that serum and liver cAMP levels 
corresponded with Abcc4 mRNA expression.  Abcc4 induction during food 
deprivation may be a response to control intracellular cyclic nucleotide 
concentrations within liver to better regulate the fasting response.  Fasting 
is known to increase NAD+/NADH and GSSG/GSH ratios within liver (21).  
Use of GSH in conjugating reactions also increases GSH conjugates, which 
are also ABCC2-4 substrates.  Moreover, upregulation of GSH synthesis 
restores redox balance and can enhance bile flow.  Altered NAD+ and 
NADH levels in Nrf2-null mice reflect the inability to cycle NADH to NAD+; 
required for glycolytic processes, which might be compensated by 
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alternative pathways as indicated by a higher fold increased NAD+/NADH 
ratios upon fasting.  This observation is consistent with a recent observation 
that PKA activates Sirt1 in NAD+ independent mechanisms (19).  However, 
the role of NAD+ in activating Sirt1 cannot be overlooked.  Lastly, fasting 
mobilizes fats from adipose tissue to liver resulting in fasting-induced 
steatosis.  As Nrf2 has been implicated in promoting steatosis, perhaps 
early Nrf2 activation during fasting is one of the cellular responses to aid 
this process and promote energy conservation in the form of TG storage 
(42). 
   
Downstream regulation of Abcc2-4 by Nrf2 is well described, yet upstream 
signaling pathways are less described.  Insulin activates Nrf2 via PI3K, 
mTOR and Akt pathways in diabetic models (40,57).  However, pathways 
contributing to fasting- dependant Nrf2 activation and subsequent target 
gene expression have not been described.  To date two in vitro studies 
illustrate that cAMP regulates Abcc3 and 4 expression (8,48).  Presently, 
cAMP/PKA pathway activators (e.g. epinephrine, glucagon,cAMP analogs, 
and food deprivation) increased ARE activity Nrf2 target gene expression in 
primary human and mouse hepatocytes, as well as mouse liver.  H89, a 
well described PKA inhibitor attenuated 8-Br-cAMP induction of ARE 
activation and Nrf2 target gene upregulation, in vitro, further supporting a 
role for the cAMP/PKA pathway.  Moreover, AMPK activators decreased 
Nrf2 target gene expression and were not increased in fasting.  Thus, the 
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data support a role for cAMP/PKA cascade as a regulator of Nrf2-ARE 
activation.      
 
An additional aspect of the current study was to identify factors downstream 
of cAMP/PKA cascade, which mediate activation of Nrf2- ARE pathway.  
The cAMP/PKA cascade activates CREB, which is also known to interact 
with Nrf2, and synergistically increase Nrf2 target gene transcription (50) .  
Because Pgc-1α is a central transcriptional co-activator to multiple nuclear 
receptors (15), we hypothesized that fasting might also modulate Nrf2 via 
Sirtuin 1- Pgc- in vivo.  Epigenetic mechanisms, 
such as acetylation/deacetylation by p300/cbp protein on lysine residues in 
the Neh1 domain of Nrf2 as well as phosphorylation/ dephosphorylation at 
serine 40 and tyrosine 568 modulate Nrf2-ARE binding (27,28,50).  Sirt1 
can decrease Nrf2 binding to ARE in vitro (28).  However, to date, no 
studies have addressed how Sirt1 regulates Nrf2 activity and subsequent 
gene expression in vivo.  The data herein illustrate that fasting mediated 
Nrf2 activation and Abcc upregulation is Sirt1 dependent. 
 
Sirt1 and Pgc-1α act in concert to activate gluconeogenesis pathways in the 
hepatocytes (46).  Mice expressing Sirt1 in liver induced Nrf2 target gene 
mRNA expression upon fasting.  However, fasting induction of Nrf2 target 
gene expression (including Abcc2-4) was muted in livers of mice with 
hepatocyte-specific Sirt1 deletion.  Moreover, fasting generally increased 
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liver Abcc2-4 mRNA expression with Sirt1 overexpression.   The above 
observations indicate towards a probable role of Sirt1 as an upstream 
regulator of Nrf2-ARE pathway. 
 
Leptin resistance is hallmark of obesity (56), which is modeled in OB mice 
(23). Conditions of obesity and steatosis increase liver Nrf2 and Abcc2-4 
expression in mice, indicating endogenous metabolites can modulate their 
expression (13,39).  Upon fasting, OB mice displayed a muted response to 
fasting, with lower Abcc2-4 and Nqo1 induction observed.  Some models of 
obesity, such as rats fed a high fat diet, are described as unable to activate 
fasting pathway over lean models (16).     
 
In summary, fasting and PKA activators increased mouse Abcc2-4 
expression in liver by Nrf2- and Sirt1-related mechanisms in mouse liver 
and hepatocytes.  Additionally, 8-Br-cAMP and PKA activating compounds 
increased Nrf2 target gene and ABCC2-4 mRNA expression in human 
hepatocytes.  Our data illustrate an undescribed role for Nrf2 as a “fasting” 
responsive transcription factor that is activated via cAMP/PKA-Sirt1 
upstream mechanisms.  
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FIGURE LEGENDS: 
FIGURE I-1: Fasting induces Abcc2-4 expression in vitro and in vivo.  
(A) Increased biliary DBSP excretion upon fasting. DBSP 
(150μmol/kg/5ml, i.p) was injected into C57Bl/6 mice (n=5 per group) either 
fed ad libitum or fasted for 18 hrs.  45 min after injection, gallbladders were 
collected and biliary DBSP content was determined spectrophotometrically 
after appropriate dilution and alkalinization of bile with 0.1N NaOH.  The 
data is represented as average ± SEM μmol of DBSP/ μl bile/ kg body 
weight.   (B) Induction of Abcc 2-4 expression in mouse liver after a 24 
hr fast-  Total RNA was isolated from livers of C57Bl/6 mice either fed ad 
libitum or fasted for 24 hrs.  Relative Abcc 2- 4 mRNA expression was 
quantified by real-time quantitative PCR.  The data is represented as 
average ± SEM fold change over the fed controls.  All data has been 
normalized to 18S rRNA.  (C) Induction of Abcc2-4 protein expression in 
mouse liver after 24 hour fasting- Crude membrane proteins were 
isolated from livers of C57Bl/6 mice either fed ad libitum or fasted for 24 
hrs.  Abcc2-4 protein expression was quantified by western blotting.  (D) 
Induction of Abcc 2-4 mRNA expression in primary mouse 
hepatocytes by 8-Br-cAMP-  Primary mouse hepatocytes were treated 
with DMSO or 8-Br-cAMP (1mM) for 24 hrs.  Total RNA was isolated 24 hrs 
after treatment and Abcc 2- 4mRNA expression was quantified using real 
time quantitative PCR.  The data is represented as average ± SEM (n=3) 
fold change over the fed controls.  All data is normalized to 18S rRNA. 
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Groups without a common letter are significantly different.  (E) Time 
dependant expression of ABCC 2-4 mRNA in Huh-7 cells by 8-Br-
cAMP-  Huh-7 cells were treated with1.0mM 8-Br-cAMP for 0, 3, 6, 12, 24 
and 48 hrs with media as the control (n=3) .  Total RNA was isolated and 
ABCC 2-4 mRNA expression was quantified using the Branched DNA 
Signal Amplification assay.  The data is represented as average RLU per 
10μg total RNA ± SEM (n=3).  (F) Induction of ABCC 2-4 mRNA 
expression in primary human hepatocytes by 8-Brc-AMP-  Primary 
human hepatocytes were treated with media, DMSO, 8-Br-cAMP (0.1 and 
1mM), epinephrine (10 and 100 μM) or glucagon (0.1 and 1 μM) for 24 hrs.  
At the end of 24 hrs cells were lysed using Lysis Mixture™.  mRNA levels of 
ABCC 2-4 were quantified using Branched DNA signal amplification assay . 
The data is represented as relative mRNA expression per 25 μl lysate 
normalized to beta actin from three human hepatocyte donors.      
 
FIGURE I-2:  Fasting induces Nrf2 target gene expression in vitro and 
in vivo. (A)  Induction of Nqo1 and Nrf2 mRNA expression in mouse 
liver after 24 hr fast-  Total RNA was isolated from livers of C57Bl/6 mice 
either fed ad libitum or fasted for 24 hrs.  Gene expression of Nqo1 was 
quantified by real-time quantitative PCR.  The data is represented as 
average ± SEM fold change over the fed controls.  All data has been 
normalized to 18S rRNA.  (B)  Induction of Nqo1 protein expression in 
mouse liver after 24 hour fasting-  Cytosolic proteins were isolated from 
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livers of C57Bl/6 (n=3) mice either fed ad libitum or fasted for 24 hrs.  Nqo1 
protein expression was quantified by western blotting.  The data is 
representative of three individual protein quantifications.  (C) Induction of 
Nqo1 and Nrf2 mRNA expression in primary mouse hepatocytes by 8-
Br-cAMP- Primary mouse hepatocytes were treated with DMSO or 8-Br-
cAMP (1mM) for 24 hrs.  Total RNA was isolated 24 hrs after treatment and 
Nqo1 and Nrf2 mRNA expressionwas quantified using real time quantitative 
PCR.  The data is represented as average ± SEM (n=3) fold change over 
the fed controls.  All data is normalized to 18S rRNA. Groups without a 
common letter are significantly different.  (D) Induction of NQO1 mRNA 
expression in primary human hepatocytes by 8-Brc-AMP- Primary 
human hepatocytes were treated with media, DMSO, 8-Br-cAMP (0.1 and 
1mM), epinephrine (10 and 100 μM) or glucagon (0.1 and 1 μM) for 24 hrs.  
At the end of 24 hrs cells were lysed using Lysis Mixture™.  mRNA levels of 
NQO1 was quantified using Branched DNA signal amplification assay . The 
data is represented as relative mRNA expression per 25 μl lysate 
normalized to beta actin from 3 human hepatocyte donors.  (E) Time 
dependant increase in Nqo1 and Nrf2 protein expression in Huh7 cells 
by 8-Br-cAMP- Huh-7 cells were treated with1.0mM 8-Br-cAMP for 0, 3, 6, 
12, 24 hrs with media as the control (n=3).  mRNA levels of NQO1 was 
quantified using Branched DNA signal amplification assay.  The data is 
represented as fold change in Nqo1 mRNA expression (n=3) .   Nqo1 
protein levels were determined by western blotting with gapdh as the 
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loading control.  Nuclear Nrf2 protein levels were measured by western 
blotting with laminB1 as loading control.    
 
FIGURE I-3: Fasting increases Abcc2-4, Nqo1 expression in Nrf2 
dependant manner.  (A)Fasting for 24 hrs induces the expression of 
Nrf2 target genes in wild type C57Bl/6 mice livers but not in Nrf2 null 
mice livers- Total RNA was isolated from livers of C57Bl/6 (n=6) and Nrf2-
null (n=6) mice either fed ad libitum or fasted for 24 hrs.  Nqo1and Abcc 2-4 
gene expression was quantified by real time quantitative PCR.  The data is 
represented as average ± SEM (n=6) fold change over the fed controls.  (B) 
Immunohistochemical staining of Abcc2- Cryosections were incubated 
with anti-Abcc2 antibody followed by incubation with AlexaFluor-conjugated 
secondary antibodies (green).  (C) Induction of Abcc2-4 protein 
expression in Nrf2-WT but not in Nrf2-null mouse liver after 24 hour 
fasting-  Crude membrane proteins were isolated from livers of C57Bl/6 
(n=2) and Nrf2 null (n=2) mice either fed ad libitum or fasted for 24 hrs.  
Nqo1, Abcc2, Abcc3 and beta actin protein expression was quantified by 
western blotting.  The data is representative of three individual protein 
quantifications.  (D) Fasting for 24 hrs decreases liver cAMP while 
increasing serum cAMP levels in Nrf2 WT but not in Nrf2 null mice.  
Serum bile acids and serum and liver cAMP levels were determined from 
serum and livers obtained from C57Bl/6 (n=4) and Nrf2 null (n=4) mice 
fasted for 24 hrs.  Data is represented as average ± SEM (n=4) fold change 
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relative to control.     (E) Fasting increases binding of Nrf2 to its 
consensus sequence-  Liver nuclear extracts were prepared from control 
and fasted C57Bl/6 mice using Procarta TF nuclear extraction kit and 
analysis for transcription factor binding was determined using a 9 plex 
Procarta TF binding assay.  The results obtained are represented as data 
normalized to TFIID. Data is expressed as Fluresence Intensity/10 μg total 
liver nuclear extract normalized to WT fed controls.  P<0.05 was considered 
statistically significant.  (F) Fasting increases hPAP and Nqo1 mRNA in 
livers of ARE-hPAP mice-  Total RNA was isolated from livers of C57Bl/6 
(n=3) and ARE-hPAP (n=3) mice either fed ad libitum or fasted for 24 hrs.  
Nqo1 and human alkaline phosphatase (hPAP) mRNA expression was 
quantified by real time quantitative PCR.  The data is represented as 
average ± SEM (n=3) fold change over the fed controls.  All data has been 
normalized to 18S rRNA.  (G) 8-Br-cAMP induces hPAP mRNA 
expression in primary mouse hepatocytes- ARE-hPAP mouse 
hepatocytes were treated with 1mM 8-Br-cAMP for 24 hrs.  Total RNA was 
isolated and ARE-hPAP mRNA expression was quantified using RT2 -PCR.  
Target gene expression was normalized to 18s rRNA.  Groups without a 
common letter are significantly different.   
 
FIGURE I-4: PKA pathway acts as upstream regulator of Nrf2-ARE 
pathway.  (A) 8-Br-cAMP induces Antioxidant Response Element 
(ARE) in Huh-7 cells- Huh7 cells were cultured to 85% conflucence and 
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transiently transfected with an Antioxidant Response Element –luciferase 
reporter construct (100ng) for 24 hrs. The cells were then treated with 
0.1mM and 1.0mM 8-Br-cAMP for 24 hrs. Luciferase activity was measured 
by dual luciferase assay with renilla luciferase as a control. The data is 
expressed as average fold induction in activity of the ARE-luciferase 
construct ± SEM (n=4).  (B) H89 inhibits 8Br-cAMP induced mRNA 
expression of hPAP- ARE-hPAP mouse hepatocytes were treated with 
1mM 8-Br-cAMP with or without H89 (10uM) for 24 hrs.  Total RNA was 
isolated and hPAP, expression was quantified using RT2 -PCR.  Target 
gene expression was normalized to 18s rRNA.  8-Br-cAMP induced (C) 
Nrf2, Nqo1 and (D) Abcc2 and 4 mRNA expression is muted by H89 co-
treatment in Nrf2 WT, but not Nrf2 null hepatocytes-  Primary mouse 
hepatocytes obtained from Nrf2+/+ or Nrf2-/- mice were treated with DMSO 
or 8-Br-cAMP (1mM) with or without H89 (20 μM) for 24 hrs.  Total RNA 
was isolated 24 hrs after treatment and Abcc2 mRNA expression was 
measured using real time quantitative PCR.  The data is represented as 
average ± SEM (n=3) fold change over the fed controls.  All data is 
normalized to 18S rRNA.  P<0.05 was considered statistically significant. 
Groups without a common letter are significantly different.  (E) Fasting 
induced upregulation of hepatic NAD+/NADH levels occurs to the 
greater extent in Nrf2 null mice- NAD+/NADH ratio was quantified in 
livers obtained from C57Bl/6 mice fasted for 24 hrs according to 
manufacturer’s protocol.  The data is represented as average ± SEM (n=4) 
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fold change over the fed controls.   (F) AMPK activators do not induce 
expression of Nrf2 target genes- Primary mouse hepatocytes were 
treated with control, AICAR (0.5mM), NAD+ (5mM) or metformin (1mM) for 
24 hrs.  Total RNA was isolated 6 hrs after treatment and mRNA expression 
of Nqo1 and Nrf2 was quantified using real time quantitative PCR.  The 
data is represented as average ± SEM (n=3) fold change over the fed 
controls.  All data is normalized to 18S rRNA. Groups without a common 
letter are significantly different.  (G)  Total AMPKα and p-AMPKα is 
attenuated in Nrf2 WT and Nrf2 null mouse livers upon fasting- 
Proteins lysates were obtained from livers of C57Bl/6 (n=2) and Nrf2 null 
(n=2) mice either fed ad libitum or fasted for 24 hrs.  Total AMPK and p-
AMPKα and gapdh protein expression was quantified by western blotting.   
 
FIGURE I-5: Changes in Nrf2-ARE pathway during fasting are Sirt1 
dependant. (A) Sirt1LKO mice demonstrate resistance to effects of 
fasting- Total RNA was isolated from livers of SirtWT (n=5) and Sirt1LKO 
(n=3) mice either fed ad libitum or fasted for 24 hrs.  Gene expression of 
Nrf2, Abcc 2-4 was quantified by real time quantitative PCR.  The data is 
represented as average ± SEM fold change over the fed controls. All data 
has been normalized to 18S rRNA.  P<0.05 was considered statistically 
significant. Groups without a common letter are significantly different.  (B) 
Sirt1OE mice demonstrate enhanced induction of Abcc2-4 and Nrf2 
target genes upon fasting- Total RNA was isolated from livers of Sirt1OE 
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(n=8) mice either fed ad libitum or fasted for 19 hrs.  Gene expression of 
Nrf2, Abcc 2-4 was quantified by real time quantitative PCR.  The data is 
represented as average ± SEM fold change over the fed controls.  Groups 
without a common letter are significantly different.  All data is normalized to 
18S rRNA.  P<0.05 was considered statistically significant. Groups without 
a common letter are significantly different.  
 
FIGURE I-6:  Nrf2 expression increases co-ordiantely with Pgc-1α and 
Sirt1 expression.   (A) Nrf2 mRNA coordinately increases with 
increasing activation of Sirt1- Huh-7 cells were cultured to 85% 
confluence and transiently transfected (50-100ng) Myc-Sirt1, 75ng Flag-
Nrf2 and 0.5µg Flag-Pgc-1α expression plasmids using Lipofectamine LTX-
plus reagent (Invitrogen, CA, USA) for 24 hrs.  The cells were then treated 
with 1.0mM 8-Br-cAMP for 24 hrs.  Endogenous Nrf2 and Pgc-1α mRNA 
expression was quantified by real time quantitative PCR.  The data is 
represented as average ± SEM (n=3) over control All data has been 
normalized to 18S rRNA. (B) Nrf2 mRNA coordinately increases with 
increasing Pgc-1α-  Huh-7 cells were cultured to 85% confluence and 
transiently transfected with (0.5-1.0 µg) Flag-Pgc-1α, 50ng Myc-Sirt1, 75ng 
Flag-Nrf2 and 0.5µg Flag-Pgc-1α expression plasmids for 24 hrs.  The cells 
were then treated with 1.0mM 8-Br-cAMP for 24 hrs.  Nrf2 and Pgc-1α 
mRNA expression was quantified by real time quantitative PCR.  The data 
is represented as average ± SEM (n=3) over control All data has been 
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normalized to 18S rRNA.  (C and D)  Pgc-1α co-immunoprecipitates with 
Nrf2 in a Sirt1 dependent manner-  Huh-7 cells were cultured to 85% 
conflucence in 6cm dishes and transiently transfected with 3.0µg Flag-
tagged Nrf2, with or without 0.75µg cMyc-tagged Sirt1 plasmid for 24 hrs.  
At the end of 24 hrs, cells were treated with 1.0mM 8-Br-cAMP for 45 mins 
and then lysed using lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.05% NP-40).  1mg of the protein lysate was incubated with Anti-FlagM2 
magnetic beads overnight in lysis buffer and immunoprecipitates were 
separated on SDS-PAGE and immunoblotted for Flag-M2 and endogenous 
Pgc-1α.  Gapdh was used as protein loading control.  
 
FIGURE I-7: Fasting effects are generally blunted in obese mice.  Total 
RNA was isolated from livers of C57Bl/6 (n=8) and OB (n=8) mice either fed 
ad libitum or fasted for 24 hrs.  Gene expression of Nrf2, Nqo1, Abcc 2- 4 
was quantified by real time quantitative PCR.  The data is represented as 
average ± SEM (n=8) fold change over the fed controls. All data has been 
normalized to 18S rRNA. 
 
FIGURE I-8: Proposed model for fasting induced activation of Nrf2-
ARE pathway and expression of downstream target genes.  Fasting 
increases circulating glucagon and epinephrine levels activating cAMP/PKA 
cascade which eventually increases pepck and Pgc-1α expression and also 
activates Sirt1; thus gluconeogenesis.  cAMP/PKA also induces Nrf2 
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binding to ARE in a Sirt1 dependant mechanisms leading to an increase in 
Nqo1, Abcc2-4 expression. It is hypothesized fasting will result in the 
production or accumulation of metabolic intermediates, which could be 
eliminated from hepatocytes via Abcc2-4.  Fasting increases NAD+/NADH 
ratios, cAMP, bile acids, lipid peroxidation, glucuronide and glutathione 
(GSH) conjugation, and decreases GSH levels within the hepatocyte.  GSH 
and glucuronide conjugates are substrates for Abcc2-4, some lipid 
peroxidation products are substrates for Abcc3.  Abcc4 transports cyclic 
nucleotides, such as cAMP and cGMP.  Overall, fasting could increase the 
hepatic efflux of metabolite conjugates and intermediates resulting from 
induction of the fasting response to maintain cellular homeostasis.   
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 44 
 
FIGURE I-3: 
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SUPPLEMENTARY INFORMATION: 
 
FIGURE 1: Induction of Pgc-1α, Pepck and Sult2a1 mRNA expression 
upon activation of fasting pathway. Adult C57Bl/6 (n=8/group) mice were 
fed ad libitum or fasted for 24 hours.  (A) 24 fasting increases Pgc-1α, 
Pepck and Sult2a1 mRNA expression- Total RNA was isolated from 
livers and gene expression of Pgc-1α and Sult2a1 was quantified by real 
time quantitative PCR.  The data is represented as average ± SEM (n=8) 
fold change over the fed controls.  All data has been normalized to 18S 
rRNA.  P<0.05 was considered statistically significant. Groups without a 
common letter are significantly different. (B) Induction of Pgc-1α mRNA 
expression in primary mouse hepatocytes by 8-Br-cAMP-  Primary 
mouse hepatocytes were treated with DMSO or 8-Br-cAMP (1mM) for 24 
hours.  Total RNA was isolated 24 hours after treatment and Abcc 2- 
4mRNA expression was quantified using real time quantitative PCR.  The 
data is represented as average ± SEM (n=3) fold change over the fed 
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controls.  All data is normalized to 18S rRNA. Groups without a common 
letter are significantly different.  
                          
 
FIGURE 2: Pgc-1α, Abcc2-4, Nqo1, Gclc and Nrf2 expression 
decreases in mouse liver after 30 hour fasting.  Adult C57Bl/6  or OB 
(n=6/group) mice were either fed ad libitum or fasted for 30 hours.  (A) 30 
hour fasting decreases mRNA expression of Pgc-1α, Abcc2-4, Nqo1, 
Gclc and Nrf2 -   Total RNA was isolated from livers and gene expression 
of Pgc-1α, Abcc2-4, Nqo1, Gclc and Nrf2 was quantified by real time 
quantitative PCR.  The data is represented as average ± SEM (n=6) fold 
change over the fed controls.  All data has been normalized to 18S rRNA.  
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P<0.05 was considered statistically significant. Groups without a common 
letter are significantly different.  (B) 30 hour fasting decreases 
expression of Abcc2-4 protein- Crude membrane proteins were isolated 
from livers of C57Bl/6 or OB (n=8) mice either fed ad libitum or fasted for 30 
hours.  Protein expression of Abcc2-4 was quantified by western blotting.   
 
 
FIGURE 3: Abcc2-4 protein expression is abolished in mouse liver 
after 48 hour fasting. Adult C57Bl/6 or OB mice (n=6/group) were either 
fed ad libitum or fasted for 48 hours.  Crude membrane proteins were 
isolated from livers of C57Bl/6 (n=8) mice either fed ad libitum or fasted for 
48 hours.  Protein expression of Abcc2-4 was quantified by western 
blotting. 
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FIGURE 4: (A) 8-Br-cAMP increases Nrf2 binding to its consensus 
sequence in Huh-7 cells.  Huh-7 cells were treated with1.0mM 8-Br-cAMP 
for 6 hours with media as the control.  Liver nuclear extracts were prepared 
from control and treated Huh-7 cells using Procarta TF nuclear extraction kit 
and analyzed for Nrf2 binding using a 9 plex Procarta TF binding assay.  
The results obtained are represented as data normalized to TFIID. Data is 
expressed as Fluresence Intensity/10 μg total liver nuclear extract 
normalized to untreated Huh-7 cells.  (B) Time dependant mRNA 
expression of NQO1 in Huh-7 cells by 8-Br-cAMP-  Huh-7 cells were 
treated with1.0mM 8-Br-cAMP for 0, 3, 6, 12, 24 and 48 hrs with media as 
the control.  Total RNA was isolated and mRNA expression of NQO1 was 
quantified using Branched DNA signal amplification assay.  The data is 
represented as average RLU per 10μg total RNA ± SEM (n=3). 
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FIGURE 5:  Activation of antioxidant response element (ARE) in Huh-7 
cells by (A) 8-Br-cAMP, and (B) glucagon and epinephrine.  Huh7 cells 
were cultured to 85% confluence and transiently transfected with 
Antioxidant response element –luciferase construct (100ng) and the empty 
vector (100ng) along with a renilla control construct (10ng) for 24 hours. 
The cells were then treated with 0.01- 2.0 mM 8-Br-cAMP, 0.1 μM or 1.0 
μM glucagon or 10 μM epinephrine for 24 hours. The luciferase activity was 
measured by dual luciferase assay with renilla luciferase as a control. The 
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data is expressed as average fold induction in activity of the ARE-luciferase 
construct ± SEM (n=4). 
 
FIGURE 6:  Fasting induces Pgc-1α and pepck expression to a similar 
extent in Nrf2 WT and Nrf2 null mice- Total RNA was isolated from livers 
of Nrf2 WT (n=6) and Nrf2 null(n=6) mice either fed ad libitum or fasted for 
24 hrs.  Gene expression of Pgc-1α and pepck was quantified by real time 
quantitative PCR.  The data is represented as average ± SEM (n=6) fold 
change over the fed controls. All data has been normalized to 18S rRNA. 
 
FIGURE 7:  8-Br-cAMP induces expression of Sirt1 in Huh-7 cells.  
Huh-7 cells transiently transfected with (0.5-1.0µg) Flag-Pgc-1α, 75ng Flag-
Nrf2 and 50ng Myc-Sirt1 expression plasmids or (50-100ng) Myc-Sirt1, 
75ng Flag-Nrf2 and 0.5µg Flag-Pgc-1α expression plasmids using 
 56 
 
Lipofectamine LTX-plus reagent (Invitrogen, CA, USA) for 24 hrs.  Cells 
were then treated with 1.0mM 8-Br-cAMP for 24 hrs.  After 24 hours, cells 
were lysed with lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% 
NP-40).  25µg protein lysate was then subject to immunoblot analysis for 
anti-cMyc tag protein. 
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TABLE I-1: 
Effect of 24 hour fasting on body weight, liver-to-body weight ratios 
and biochemical profile:  Adult C57Bl/6 and ob/ob mice (n=8/group) were 
fed (ad libitum) or fasted 24 hours.  Average liver weights, liver-to-body 
weight ratios, serum glucose (mg/dl), serum and liver triglycerides (mg/dl) 
and serum NEFA (mmol/dl) were determined. P<0.05 was considered 
statistically significant. Groups without a common letter are significantly 
different. 
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ABSTRACT  
Nuclear receptors (NR), CAR, PXR, FXR, PPARα, and Nrf2 are 
transcriptional regulators of transporter expression in liver in coordination 
with Phase-I and -II biotransformation enzymes. NAFLD markedly alters 
hepatic transporter expression in mice. Caloric restriction (CR) is a common 
regimen to treat NAFLD and proven model to activate Sirtuin1 deacetylase 
activity in liver conferring protection against steatosis. Purpose of this study 
was to expand on currently negligible information to evaluate whether CR 
affects hepatic transporter expression in livers from lean mice and “reverse” 
transporter expression changes observed with steatosis. Adult lean 
(C57Bl/6) and obese (ob/ob, OB) mice were fed ad libitum or placed on a 
40% (kCal) reduced diet. CR decreased hepatic triglyceride levels in both 
mice, but not to the same degree in livers from OB mice. CR decreased 
Oatp1a1, Oatp1b2 (~90%) as well as Bsep, Bcrp (~40%) mRNA and 
protein expression in lean but not OB mice. CR increased Abcc2 mRNA 
expression by ~2 fold in OB livers only. However, protein expression 
increased in both lean and OB mice, reversing basal downregulation of 
Abcc2 in OB mice to a level comparable to lean fed controls. Steatotic livers 
from OB mice show increased Abcc1, 3, 4 and 5 mRNA expression. CR 
decreased Abcc3 protein expression in lean mice but increased it in OB 
livers. CR did not alter Abcc1, 4 and 5 mRNA expression in lean mice but 
significantly decreased their expression in OB mouse livers. Abcc4 protein 
expression increased in lean and OB mice upon CR. In steatotic livers from 
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OB mice; AhR, PXR, NFκβ, Nrf2, CREB, CAR and PPAR binding to 
respective RE increased by 147-275% but FXR binding decreased by 60%. 
This increased binding in hepatic nuclear fractions from OB mice was 
reversed by CR and mirrored by respective target gene expression. In 
summary, CR can “reverse” expression of some transporters in liver, but 
not all. Overall, these data indicate a potential to restore hepatic disposition 
changes associated with obesity through CR. 
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INTRODUCTION:  
Non-Alcoholic Fatty Liver Disease (NAFLD) or steatosis is defined as lipid 
accumulation exceeding 5% by weight in hepatocytes in the absence of 
substantial alcohol intake (McCullough, 2006), often with increased hepatic 
triglyceride accumulation. Metabolic syndrome is considered to be the 
underlying cause of NAFLD (Browning and Horton, 2004).  It is estimated 
that more than 86% of US adults will be overweight or obese, and more 
than 50% obese by the year 2030 (Wang et al., 2008).  In the United 
States, the prevalence of NAFLD alone, or in combination with increased 
liver enzymes in serum, was 3.1% and 16.4% among adults, respectively 
(Browning et al., 2004; Lazo et al., 2011).  With no intervention, NAFLD can 
progress to Non-alcoholic steatohepatitis (NASH), which is characterized by 
increased hepatic inflammation and cellular injury, and then cirrhosis, which 
permanently scars the liver (Angulo and Lindor, 2002). 
Epidemiological and clinical studies demonstrate changed 
pharmacokinetic and –dynamic parameters of some drugs in obese 
subjects (Abernethy and Greenblatt, 1986; Fideleff et al., 2006; Jain et al., 
2011).    NAFLD and NASH are also associated with altered 
pharmacokinetics of some drugs (e.g ezetimibe, acetaminophen) as well 
as, altered endogenous metabolite levels, such as cholesterol and bilirubin 
(Barshop et al., 2011; Schrieber et al., 2011; Simonen et al., 2011; Kumar 
et al., 2012).  For example, acetaminophen-glucuronide concentration in 
plasma and urine was higher in children with NAFLD (Barshop et al., 2011), 
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which is similar to what has been reported in db/db mice that exhibit hepatic 
steatosis (More et al., 2012).  This likely occurs because Phase-I, -II 
biotransformation enzyme, and drug transporter expression is altered 
compared to non-steatotic livers (Slitt et al., 2003; Lickteig et al., 2007; 
Fisher et al., 2009; Xu et al., 2012).   
Diet (caloric restriction, CR) and exercise are the recommended 
therapeutic intervention to treat NAFLD and reverse hepatic fat 
accumulation (2002; Deng et al., 2007; Larson-Meyer et al., 2008; 
Vuppalanchi and Chalasani, 2009; Zelber-Sagi et al., 2011).  For example, 
a regimen of diet and exercise decreased hepatic steatosis and serum 
lipids in overweight subjects with NAFLD (Larson-Meyer, 2008).   Also, 
vigorous physical activity was associated with decreased adjusted odds of 
having NASH in adults with NAFLD (Kistler et al., 2011).   CR decreases 
systemic glucose levels, increases fatty acid oxidation, and decreases the 
fat-to-body weight ratio (Frame et al., 1998; Mahoney et al., 2006; Bruss et 
al., 2010).   
Beneficial effects of CR are attributed to of Sirtuin 1 (Sirt1), a 
deacetylase that activates gluconeogenic and fatty acid oxidation gene 
expression via deacetylation and upregulation of Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (Pgc-1α), a transcriptional 
co-activator  (Canto and Auwerx, 2009; Jeninga et al., 2010).  The AMP-
Kinase (AMPK) secondary messenger pathway is an upstream activator of 
the Sirt-Pgc1-α cascade during CR.  AMPK activates Sirt1 deacetylase in 
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response to changes in redox status (NAD+/NADH ratio) of the cell (Hou et 
al., 2008; Lan et al., 2008; Canto et al., 2009).   Steatotic livers exhibit 
decreased AMPK pathway activity in rodents and reversal of this activity 
reverses fatty liver (You et al., 2008; Ha et al., 2011; Zheng et al., 2011). 
Interestingly, CR alters activity and expression of of various 
biotransformation enzymes such as Sult2a1, Cyp2b10, Ugt1a1, CYp4a14 in 
liver (Zhang et al.; Maglich et al., 2004; Corton and Brown-Borg, 2005).   
However, to our knowledge, no studies have shown how CR actually affects 
drug transporter expression in livers of obese mice, which have hepatic 
steatosis and better mimic the population most likely to undergo 
intervention. 
Nuclear factor-E2-related factor 2 (Nrf2) is a transcription factor, 
which upregulates cytoprotective mechanisms in response oxidative stress 
and drug-induced liver injury, via upregulation of antioxidant enzymes (e.g. 
Superoxide dismutase, Sod-1; Glutamate cysteine ligase catalytic subunit, 
Gclc), biotransformation enzymes (e.g. Glutathione S-transferase a1, 
Gsta1; Heme oxygenase 1, Ho-1; Nad(p)h:oxidoreductase 1, Nqo1) and 
ATP Binding Cassette transporters (Multidrug resistance-associated 
protein, Mrp2) (Itoh et al., 2003; Maher et al., 2007).  Multiple studies have 
shown an association between Nrf2 activation and ATP Binding Cassette 
(Abcc) transporter induction (CITE).  Moreover, Nrf2 binding and target 
gene expression is increased in steatotic livers (Cheng et al., 2008; 
Hardwick et al., 2010; Kay et al., 2011; Xu et al., 2011).    
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In the present study we hypothesized that CR would reverse the NR 
and drug transporter expression changes previously observed in obesity-
induced hepatic steatosis (Cheng et al., 2008; Xu et al., 2012).   Given the 
well-defined association of Nrf2 with Abcc transporter induction, emphasis 
was placed on the Nrf2 pathway, but other NRs that have been described to 
regulate transporter expression were also evaluated.  Our data herein 
illustrate that CR differentially regulates NR, biotransformation enzyme, and 
transporter expression in livers from C57Bl/6 (WT) and Lepob/ob (OB) mice.  
Furthermore, AMPK and Sirt1 activators differentially modulated transporter 
and NR expression in lean and steatotic hepatocytes.  
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METHODS 
Animals and treatments. Mice were housed in a temperature-, light-, and 
humidity-controlled environment in cages with corn cob bedding.  The mice 
were fed Harlan Teklad LM-485 Mouse/rat sterilizable diet (Harlan 
Laboratories, Madison, WI) ad libitum.  Adult male C57BL/6 (WT) and 
Lepob/ob (OB) (B6.V-Lepob/J, stock no. 0000632) mice were purchased from 
Jackson Labs (Bar Harbor, ME).  After acclimation for 2 weeks, mice were 
transferred on to a purified diet (AIN93-G) obtained from Test Diet, IN, USA 
and allowed to acclimatize for a period of 2 weeks.    The average caloric 
consumption was calculated for each mouse over a period of 10 days.  WT 
(n=7) and OB mice (n=7) were fed ad libitum for 10 weeks.  Alternatively, 
WT (n=10) and OB mice (n=10) were fed a 40% reduced caloric diet for 10 
weeks with access to water ad libitum.  Body weight and food consumption 
were monitored at least once per week for the entire study.  The study was 
terminated when weights were constant for several weeks.  The study was 
carried at University of Rhode Island and IACUC approved.   
 
RNA Isolation and mRNA Quantification. Total RNA was isolated from 
the collected livers by phenol-chloroform extraction with RNAzol B reagent 
(Tel-Test Inc., Friendswood, TX) according to the manufacturer’s 
instructions.  RNA concentration was determined by measuring UV 
absorbance at 260 nm using NanoDrop™ and the integrity was confirmed 
by formaldehyde gel electrophoresis. The total RNA samples were stored at 
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-80°C until further use for analysis.  The total RNA samples were analyzed 
for mRNA quantification using Branched DNA signal amplification assay 
(Quantigene 1.0 assay), obtained from Panomics Inc., CA, USA.  RNA 
obtained from hepatocyte treatment was quantified using RT2-PCR 
methods as described in (Xu et al., 2011) 
Tissue homogenate, membrane, and cytosol preparation.  Liver 
homogenates were obtained by homogenization (1:9, tissue:buffer ratio) 
with RIPA (Tris 50mM, NaCl 150 mM, SDS 0.1 % and TritonX-100 1.0%) 
and short centrifugation at 14000xg to remove the debris.  For transporter 
western blots, liver membrane and cytosol fractions were obtained as 
previously described (Aleksunes et al., 2006; Cheng et al., 2008).   Briefly, 
tissues were homogenized 150mM sucrose/10mM tris-HCl (ST) buffer (1:9 
ratio), pH 7.5, using a Potter Elevejem motorized homogenizer.  
Homogenates were centrifuged at 100,000 x g for 1 hour at 4°C.  The 
resulting supernatant (cytosolic fraction) was saved and pellets were re-
suspended in ST buffer (Cheng et al., 2008; More and Slitt, 2011). 
Western Blotting. 50µg protein lysates were solubilized in Laemmli buffer 
containing β-mercaptoethanol and electrophoretically separated by SDS-
PAGE (8% for Mrps and 10% for Oatps, 12% for cytosolic, nuclear and 
homogenate samples) at 200V for 50 min and transferred onto a PVDF 
membrane at 100V for 30-45 min or at 75V for 1.5 hours. The membrane 
was blocked overnight with 5% Non fat dry milk (NFDM) in phosphate-
buffered saline with 0.05% Tween 20 (PBS/T).  After blocking, the 
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membrane was incubated with primary antibodies diluted in 5%NFDM in 
PBS/T or TBS/T for 2 hours and subsequently with corresponding 
horseradish peroxidase labeled secondary antibodies also diluted in 
5%NFDM in PBS/T as mentioned in table 3.  The blots were incubated in 
Pierce ECL-Plus western blot detection reagent (Thermo Fisher Scientific, 
Rockford, IL,USA) and exposed to X-ray film for developing and 
visualization.  The blots were quantified using ImageQuant software (Bio-
Rad, Hercules, CA).  Oatp1a4 and 2b1 western blots were attempted, but 
not successful.   Details of the antibodies used are as previously published 
(More and Slitt, 2011).  
 
Transcription factor binding assay.  Nuclear extracts were isolated from 
livers using a TF Procarta nuclear extraction kit (Panomics Inc, CA, USA) 
and protein concentrations were measured with BCA protein assay (Pierce, 
Rockford, IL, USA).  The resulting fractions were checked for enrichment of 
nuclear proteins by western blot with Lamin B1 antibody.  Nrf2, AhR, Pxr, 
Fxr, binding to respective consensus sequences was quantified using a 
Procarta TF custom array (Affymetrix, CA) using 10µg nuclear extract 
protein per sample according to manufacturer’s instructions and published 
work (Xu et al., 2012).  Ppar assays in the kit determine the binding of TFs 
to the consensus Ppar cis-response elements and does not differentiate 
between DNA binding of Pparα from that of other Ppar family members, 
including Pparβ and Pparγ.  Hence, data for Ppar binding has not been 
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presented. Samples were analyzed using a Luminex Bio-Plex 200 array 
reader with Luminex 100 xMAP technology, and data were acquired using 
Bio-Plex Manager software (version 5.0). Data was acquired by a Luminex 
Bio-plexTM 200 Array reader with Luminex 100 X-MAP technology, and data 
were acquired using Bio-Plex Data Manager Software Version 5.0 (Bio-
Rad). All data was normalized to TFIID binding activity. 
 
Primary mouse hepatocyte isolation.  Primary mouse hepatocytes were 
obtained from adult WT and OB mice livers using a two-step collagenase 
perfusion; 1x106 cells/well in 2 mL completed medium (MEM supplied with 
10% FBS) were seeded on collagen-coated 6-well plates. After cell 
attachment (~4 h), they were cultured in serum-free MEM containing 1% 
ITS supplement (Invitrogen, CA). Approximately 24 hours post-plating, 
hepatocytes were treated with control (media or 0.01% DMSO), AICAR 
(0.5mM), NAD+ (5mM) or metformin (1mM) for 6 hours. Total RNA was 
isolated from TRIzol reagent (Invitrogen, CA) according to the 
manufacturer’s instructions. 
 
Heatmap and cluster analysis.  mRNA expression of genes quantified in 
vivo and in vitro were plotted on a heatmap using the R software 
environment (R Foundation for Statistical Computing, Vienna, Austria).  The 
genes in WT and OB CR groups were normalized to their respective ad 
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libitum controls and the fold changes relative to control were used for 
heatmap analysis. 
 
Statistics.  The statistical significance of differences was determined by 
Duncan’s factorial ANOVA test.  Letters different from each other represent 
a statistical difference between groups (p≤0.05). 
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RESULTS 
CR decreases body weight, hepatic lipid and glutathione content in 
WT and OB mice.  At 9 weeks, CR decreased average body weight by 
30% and 12% in WT and OB mice, respectively (Fig. 1A).  CR decreased 
the average liver weight and liver-to-body weight ratio in both genotypes, 
with a greater decrease in WT mice (Table 1).  CR also decreased serum 
TG (50% in WT and 11% in OB), serum glucose (50% in WT and 20% in 
OB), and increased Non-esterified fatty acid (NEFA) levels (1.6 fold in WT 
and 2 fold in OB).  Additionally, CR decreased micro and macrovesicular 
vacuolation in both WT and OB mice, but more so in WT mice.  Similarly, 
glucagon expression was stimulated in OB mice undergoing CR (Table 2).     
CR significantly decreased serum insulin levels in both WT and OB mice 
(80% and 40% respectively), and leptin levels which were undetectable in 
OB mouse serum. CR decreased hepatic glutathione (GSH) by 60% in WT 
and 30% in OB mice (Fig. 1C).  Overall, OB mice were relatively more 
resistant to CR than WT mice with regard to weight loss and reversal of 
steatosis, which is consistent with a previous observation (Sloan et al., 
2011). 
 
CR increases expression of gluconeogenic genes and gluconeogenic 
hormones, decreases expression of lipogenic genes and insulin 
levels.  CR induces glucagon secretion to increase mitochondrial 
biogenesis and upregulate glucose production.  This well characterized 
 73 
 
response results in the induction of genes needed to increase 
gluconeogenesis (Bordone and Guarente, 2005).  Therefore, genes known 
to be regulated by CR were measured to further confirm response to the 
food restriction.  CR increased expression of gluconeogenic genes Pgc-1α 
and Pepck in WT mouse livers (2 and 3.5 fold, respectively), however this 
increase was blunted in OB mouse livers (Fig. 1D), which has been 
previously described  
(ref).  Conversely, mRNA expression of the lipogenic master regulator, 
Srebp-1c, was decreased in WT mouse livers but remained unchanged in 
OB mouse liver after CR (Fig. 1D).   
 
Effect of CR on Phase I biotransformation enzyme expression in livers 
of WT and OB mice.  Phase I biotransformation enzymes are typically 
downstream target genes for NRs (Waxman, 1999; Xu et al., 2005) and are 
often measured as indirect markers of NR activation/repression.  Therefore, 
several Cyps described to be regulated via NR activation were measured in 
WT and OB mice fed AL or after CR.  Consistent with previous observations 
(Cheng et al., 2008), Cyp2b10, Cyp3a11 and Cyp4a14 basal expression 
was higher in OB mice compared to WT mice (Fig. 2A). In contrast, Cyp7a1 
and Cyp7b1 basal expression was lower in OB mouse livers as compared 
to WT mice (Fig. 2A).  CR increased expression of Cyp2b10 and Cyp4a14 
mRNA expression in WT but to a lower extent in OB mouse livers, whereas 
Cyp3a11 mRNA expression remained unchanged.  In contrast, CR 
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significantly decreased expression of Cyp7b1 in both WT and OB mouse 
livers (Fig. 2A).  CR did not affect Cyp7a1 mRNA expression in WT mice, 
but increased Cy7a1 mRNA expression in livers from OB mice (Fig. 2A).   
 
Effect of CR on Antioxidant and Phase II biotransformation enzyme 
expression in livers of WT and OB mice.  Previous work by our group 
and others have shown that Nrf2 and Nrf2 target gene expression is 
increased in livers of OB mice (Hardwick et al., 2010; Xu et al., 2012).  
Compared to WT, OB mouse livers had increased Gclc, Gsta1, Nqo1, and 
Ho-1 mRNA expression (Fig. 2B).  Consistent with hepatic GSH 
concentrations, CR decreased expression of Gclc in both WT and OB 
mouse livers (Fig. 2B).   CR significantly increased Nqo1, Sod1 and Gsta1 
in livers of WT mice.  In livers from OB mice, CR decreased Gsta1 
expression, but not Nqo1 and Sod1 expression (Fig. 2B).  Ho-1 expression 
was equivalent in livers of WT mice fed ad libitum or on CR, whereas CR 
decreased Ho-1 by about 50% in livers of OB mice.  
 
Effect of CR on Oatp expression in livers of WT and OB mice.  
Consistent with previous observations  , Oatp1a1 and 1a4 expression was 
lower in livers of WT than OB mice and Oatp1b2 expression was 
comparable between the two genotypes (Fig. 3A).  CR decreased Oatp1a1 
and 1b2 mRNA, but not 1a4 mRNA expression in livers of WT mice (Fig. 
3A) (Zhang et al., 2010).  Oatp1a1 and 1b2 expression remained 
 75 
 
suppressed in livers OB mice even after CR.  Lastly, Oatp1a1 protein 
expression was relatively undetectable in livers from OB mice, consistent 
with Cheng et al., 2008.  Oatp1a1 protein expression was undetectable in 
livers from WT and OB mice after CR (Fig. 3B).  
 
Effect of CR on Abc transporter expression in livers of WT and OB 
mice.  OB mice had lower Abcb11 and Abcc2 expression and equivalent 
Abcg2 expression compared to livers from ad libitum fed WT mice (Fig. 4A 
and 4B).  As depicted in Fig. 4A, CR decreased mRNA and protein 
expression of Abcb11 and Abcg2 in livers from WT mice, but not in the OB 
mice (Fig. 4A and 4B).  On the other hand, Abcc2 expression was similar in 
WT mice fed ad libitum or under CR, whereas CR increased Abcc2 mRNA 
expression (Fig. 4A).  CR increased Abcc2 protein expression in both WT 
and OB livers.  
Abcc1, 3-6 mRNA expression was increased in livers of OB 
compared to ad libitum fed WT mice (Fig. 4A), consistent with previous 
reports (Cheng et al., 2008; Hardwick et al., 2011).  In WT mouse livers, 
Abcc3 mRNA and protein expression decreased upon CR, with no 
observable change in Abcc1 and 5 mRNA expression (Fig. 4A and 4B).  
Conversely, Abcc4 mRNA was unaltered, but protein expression increased 
upon CR in WT mouse livers (Fig. 4A and 4B).  CR decreased Abcc1 and 5 
expression in OB mouse livers.  Abcc3 mRNA expression decreased upon 
CR, however this change did not translate into decreased protein 
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expression and Abcc4 mRNA and protein expression remained unchanged 
in OB mouse livers upon CR (Fig. 4A and 4B).  CR did not alter Abcc6 
expression in either WT or OB mice.     
 
Transcription factor binding activity in WT and OB mouse livers upon 
CR. Transcription factor binding to prototypical consensus sequences was 
also determined in nuclear fractions isolated from liver (Fig. 5).  Ahr, Creb, 
and Pxr binding was increased in liver nuclear fractions from OB mice 
compared to WT mice.  In WT mice, CR slightly decreased Ahr, Fxr, and 
Nrf2 binding and did not affect Creb or PXR binding.  In OB mice, CR 
markedly decreased AhR, Creb, and Nrf2 binding. 
To determine whether prototypical targets of these transcription factors 
were affected similarly by CR and the potential differences between the WT 
and OB livers on CR, simples heatmap was created (Fig. 5B).  As seen 
from the heatmap created, the prototypical target genes of Car, Ahr, Fxr, 
Pxr and Nrf2 were regulated similarly in WT livers.  However, in the OB 
livers, effect of CR was not consistent amongst the prototypical targets of 
transcription factors such as Car, while in other cases the target gene 
expression was opposite in OB livers as compared to WT such as in case 
of Nrf2.  These observations are consistent with the transcription factor 
binding data as seen in (Fig. 5A).      
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Effect of AMPK and Sirt1 activators on Abcc and NR induction in 
hepatocytes obtained from WT and OB mice.  AMPKinase pathway is an 
important CR signal transduction pathway upstream of transcription factor 
activation.  Hence, primary mouse hepatocytes were isolated from 11-week 
old WT and OB mice and treated with pharmacological Ampk (AICAR) and 
Sirt1 (NAD+) activators (Figure 6).  Abcc2 and 3 mRNA expression was 
increased about 3 fold in hepatocytes isolated from OB mice compared to 
WT mice (Fig. 3A), which is similar to what has been observed in intact 
livers from WT and OB mice of the same age (Cheng et al., 2008). 
Treatment with AMPK activators (AICAR, NAD+) significantly increased 
mRNA expression of Abcc2 and Abcc3 in WT mouse hepatocytes (Fig. 6A).  
As opposed to lean hepatocytes, AICAR and NAD+ treatment decreased 
Abcc2 and 3 mRNA expression in steatotic hepatocytes, thus reversing 
their expression back to normal levels.  The effect of AICAR and NAD+ 
treatment on NR expression was also evaluated (Fig. 6B).  Car mRNA 
expression was increased about 50% above control in hepatocytes isolated 
from OB mice compared to WT mice (Fig. 3A), which is similar to what was 
observed in intact livers from WT and OB mice of the same age (Xu et al., 
2012).  Fxr, Nrf2, and Pxr expression was equivocal between WT and OB 
mice, which is different from what was observed in intact livers from WT 
and OB mice of the same age (Xu et al., 2012).  AICAR and NAD+ 
treatment increased CAR, decreased Nrf2, and did not change PXR 
expression in WT hepatocytes.  AICAR and NAD+ treatment increased 
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CAR, decreased Nrf2, and did not change PXR expression in WT 
hepatocytes.  FXR was decreased by AICAR, but not NAD+.  In OB 
hepatocytes, CAR expression was not affected by either treatment, AICAR 
decreased FXR, but NAD+ did not.  AICAR and NAD+ treatment decreased 
Nrf2 mRNA expression.  PXR expression was decreased by AICAR, but not 
NAD+ treatment. 
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DISCUSSION 
The following study demonstrates that CR affected the expression of drug 
transporters in conjunction with alterations in NR and NR-target gene 
expression in conjunction with weight loss and decreased liver lipid content.  
As CR is known to activate Ampk and Sirt1 dependent pathways, the work 
herein demonstrated that AICAR and NAD+ can modulate transporter and 
NR expression in hepatocytes from WT and OB mice.  Treatment with 
AICAR and NAD+ indicated that AMPK and Sirt1 are likley upstream 
regulators of NR and Abcc transporter expression.  Lastly, our work 
illustrates that CR produced differential gene expression patterns in the 
lean or obese condition for both hepatocytes and in mice. 
 
Current study demonstrates that CR affects expression of some Phase-I, -
II, and transporters in liver.  In lean mice, mRNA expression of Cyp2b10, 
Cyp4a14 increased (as previously published by (Corton et al., 2004; Zhang 
et al., 2010)) whereas Cyp7b1 decreased while Cyp7a1 and CYp3a11 
remain unchanged.  mRNA expression of phase II enzymes, Gsta-1, Nqo1 
and Sod1 increased while that of Gclc decreased and Ho1 mRNA 
expression remained unchanged.  CR decreased mRNA expression of 
Oatp1a1, Oapt1a4 and Oatp1b2 with proteins following a similar trend as 
mRNA.  Our observations in part agree with previously published data by 
(Zhang et al., 2010).  mRNA expression of efflux transporters of the ABC 
family did not follow a specific pattern.  While Abcb4 and Abcc4 mRNA 
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expression increased upon CR, with Abcc2 expression showing an 
increasing trend.  Abcb11, Abcc3, Abcg2 expression decreased and Abcc1, 
Abcc5 and Abcc6 expression remained unchanged in the lean mice upon 
CR.  On the other hand, Abcc2 protein expression demonstrated an 
increase along with Abcc4 in the lean CR livers.  Abcc3 and Abcg2 protein 
expression mirrored the mRNA expression showing a decrease in 
expression upon CR.   
In OB mouse livers, CR did not cause significant changes in mRNA 
expression of Phase-I enzymes as compared to lean livers.  Cyp4a14 and 
Cyp7a1 mRNA expression increased while Cy2b10, Cyp3a11 remained 
unchanged and Cyp7b1 mRNA expression decreased upon CR.  In obese 
CR livers, Gsta-1, Gclc, Ho1 mRNA expression decreased while Nqo1 and 
Sod1 expression remained unchanged.  mRNA and protein expression of 
Oatp1a1, Oatp1a4 and Oatp1b2 remained unchanged in the obese livers 
upon CR.  CR did not change mRNA expression of Abcb4, Abcb11, Abcc4 
and Abcc6, whereas it decreased the expression of Abcc1, Abcc3, Abcc5, 
Abcg2 and resulted in an increased mRNA expression of Abcc2.  Protein 
expression in these livers followed the mRNA expression pattern; Abcc2 
with an increase, Abcc4 with no change and Abcg2 with a decrease in 
expression respectively while Abcc3 protein expression remained 
unchanged although mRNA expression demonstrated a decrease.  
Observations with transporter expression indicate towards a complex 
upstream multiple pathway regulation in models of CR. 
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Biotransformation enzymes and transporters are regulated by various 
nuclear receptors and transcription factors such as Pxr, Fxr, Car, Nrf2, Ahr 
(Xu et al., 2005).  To identify hierarchal relationhip and co-ordinate 
regulation between different drug metabolizing enzymes, transporters and 
nuclear receptors, preliminary cluster analysis on mRNA expression 
obtained from in vivo and in vitro studies was performed.  CR had a 
differential effect on expression of many genes of interest in the OB mice as 
compared to the WT mouse livers.  However, in both OB and WT mice, 
genes of interest clustered in similar groups indicating that absence of leptin 
interferes with the effects of CR.  As seen in Fig. 8, genes that were 
similarly regulated in both WT and OB mouse livers included Pparα, Car, 
Nrf1, Pepck, Sod1, Cyp2b10, Cyp3a11, Cyp4a14, Cyp7a1, Oatp1a4, 
Abcc2, Abcb4.  mRNA expression of Abcc5, Ho1, Abcc6, Keap1, Gsta1, 
Nqo1, Pgc-1α were positively upregulated in the WT mouse livers by CR, 
were either unchanged in OB mice or decreased in expression.  On the 
other hand CR decreased Nrf2, Abcb11, Oatp1b2, Fabp, shp, Hnf1α, 
Cyp1a1, Gclc, Abcg2, Abcc3, lrh, Srebp1, Abcc1, Cyp7b1, Oatp1a1 in the 
WT mouse livers but increased or remained unchanged in expression in the 
OB mouse livers.   
CR induced activation of Transcriptional Pathways regulating transporter 
expression: 
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Activation of metabolic pathways during CR is mediated physiologically by 
various cytokines and hormones; leptin, insulin, glucagon being considered 
pivotal in relaying important intracellular signals.  CR is known to increase 
serum glucagon, decrease insulin as well as reverse the increases in leptin 
levels (Takemori et al., 2011).  AMPK pathway is regarded as one of the 
major secondary pathways delegating intracellular signals of CR, inhibiting 
gluconeogenic pathway activity and increasing fatty acid oxidation as well 
as glucose uptake into cells.  Pparα and γ regulate pathways responsible 
for fatty acid oxidation and synthesis respectively (Tontonoz and 
Spiegelman, 2008; Pyper et al., 2010).  PPAR alpha is activated in models 
of CR via ligand dependant and independent activation by Pgc-1 α via 
Protein Kinase A and AMPKinase secondary messenger pathways 
(Rodgers et al., 2008).  Higher expression of Pparα in steatotic livers could 
be a result of fatty acid- ligand dependant activation of Pparα.   Previous 
studies have demonstrated Pparα to be the downstream target of AMPK 
activation via leptin (Lee et al., 2002; Suzuki et al., 2007).  In the study 
herein, CR likely activated Pparα as observed by increased mRNA 
expression of Pparα target gene Cyp4a14 in WT mouse liver along with an 
important coactivator Pgc-1α (Maglich et al., 2004; Corton and Brown-Borg, 
2005).    With leptin signaling mutated in livers of OB mice, the signal 
transduction is hampered and hence Cyp4a14, Pcg-1α (Fig. 1C and 2A) 
were not activated in these livers.  Consistent with these observations, CR 
increased Abcc4 expression in livers of wild type mice indicating Pparα as 
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an upstream regulator of Abcc4 expression during CR.  Endogenous 
metabolites such as cAMP and cGMP being substrates for Abcc3 and 
Abcc4 (Chandra et al., 2005; Sassi et al., 2008), the increase in expression 
of Abcc4 could attributed to increased concentrations of these substrates 
owing to activation of PKA and AMPK pathways during CR (Jeninga et al., 
2010).   In steatotic OB livers, higher fold activation of Pparα does not 
translate to increased Abcc4 activation upon CR which may be due to 
inefficient response in these livers to activation of fatty acid oxidation 
pathways, indicating as mentioned earlier a resistance to CR induced 
weight loss and steatosis reversal.  
Apart from metabolic pathways, activation of Pgc-1α during CR marks an 
important step in mediating biotransformation pathways too.  Pgc-1α is a 
known co-activator of Car (Ding et al., 2006), Fxr (Zhang et al., 2004), 
Hnf4α (Louet et al., 2002), Pxr (Eloranta et al., 2005) pathways.  In WT 
mice, CR induced mRNA expression of Car, Cyp2b10.  Car is known to 
activate Abcc2 by certain xenobiotic compounds (Aleksunes and Klaassen, 
2012).  As observed in Fig. 4A, Abcc2 expression follows a pattern similar 
to Car and Cyp2b10 as well as gets clustered with Car in the hierarchal tree 
(Fig. XX).  Similarly, Pparα, Car, Nrf1, Pepck, Sod1, Cyp2b10, Cyp3a11, 
Cyp4a14, Cyp7a1, Oatp1a4, Abcc2 all cluster together indicating that 
AMPK-Pgc-1α-Pparα cascade activation occurs upstream of Car, Pxr and 
Fxr activation.  Our observations in WT mice reflect previously published 
work (Zhang et al., 2010).   
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Nrf2-ARE pathway is an upstream regulator of various Phase-II 
metabolizing enzymes as well as Abc transporters along with a battery of 
genes responsive to oxidative stress.  It has been previously reported that 
CR restriction induces Nrf2 expression (Pearson et al., 2008).  The 
observations made in the above study differed from previously made 
observations by , but in agreement with recently published data by (Zhang 
et al., 2010).  Along with mRNA, binding of Nrf2 decreased in both WT and 
OB mouse livers correlates with the decrease in liver triglycerides, NEFA, 
and an overall decrease in steatosis.  Genes which clustered together with 
Nrf2 include Abcb11, Oatp1b2, Hnf1α in WT mouse livers.  Previous reports 
indicate that, in some models Nrf2 is a positive regulator of Abcb11 (Xu et 
al., 2010), interacts with Hnf1α and also regulates Oatp1b2 (Tanaka et al., 
2009).  Nrf2 also interacts with Ahr (Wakabayashi et al., 2010) increasing 
Ahr activity and target gene expression.  Ahr binding co-ordinately 
decreases with Nrf2 binding both WT and OB livers along with decrease in 
Cyp1a1 expression, indicating that Nrf2-Ahr cascade regulates the 
expression of genes clustered together with Nrf2.   
From correlation studies and the heatmap analyses, it is clear that effect of 
CR on WT and OB livers is different.  Model of steatotic liver used in this 
study being the Lepob/ob, leptin deficient mice, importance of leptin axis in 
regulating downstream effects of CR on expression of transcription factors 
and drug processing genes is evident.  Serum leptin along with adiponectin 
levels are known to correlate with the severity of steatosis (Lebensztejn et 
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al., 2009; Ayonrinde et al., 2011).  Hepatic and central leptin resistance is 
known to cause insulin resistance and obesity (Scarpace and Zhang, 2009).  
CR and exercise being AASLD recommended regimen to reverse NAFLD, 
the observations with leptin deficient models demonstrates a potential 
difference in the steatotic human population response to drug metabolizing 
enzyme and transporter changes upon CR.  While fat content of the liver 
significantly decreases in the steatotic liver upon CR, the 
biotransformational pathways are not completely reversed in these models.  
With a significant portion of obese-steatotic population undergoing CR the 
altered metabolic pathways may indicate an altered vectorial disposition 
or/and pharmacokinetics of drugs, endogenous metabolites and 
environmental toxicants.  Endogenous metabolites such as glucuronide 
conjugates of bile acids, bilirubin, cAMP/cGMP, glutathione conjugates and 
lipid peroxidation products such as arachidonic acid form substrates for the 
ABC transporters (Klaassen and Aleksunes, 2010).  While CR in WT/lean 
liver alters the expression of these transporters to potentially accommodate 
the metabolite concentrations in the hepatocytes, OB/steatotic livers do not 
demonstrate expression changes.  Inability to achieve these transporter 
changes could indicate towards increased levels of metabolites in the 
hepatocyte which could have adverse outcomes.  As an example, previous 
studies have published an increase in serum bilurubin levels and bile acid 
flow upon CR (Ferland et al., 1989; De Guzman et al., 2012).  Bilirubin and 
bile acid conjugates form substrates for Abcc2.  In WT livers CR while there 
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in an increase in Abcc2 expression, there is no change in Abcc2 expression 
in the OB livers indicating a potentially higher concentration of these 
metabolites in the liver.  Unchanged Abcc2 and Abcg2 expression may 
indicate towards a higher bile acid level in livers of OB mice, which 
potentially indicates an aberrant vectorial disposition of these substrates.  
Inability of steatotic liver to reverse Abcc2 and Abcg2 expression upon CR 
may have important consequences on disposition and accumulation of 
drugs and xenobiotics transported by these membrane proteins.   
All the above observations indicate that activation of CR pathways can only 
partly reverse the changes in drug metabolizing enzyme and transporter 
expression occurring due to fat deposition in the liver.  Leptin appears to 
play an important role in upstream regulation of pathways that relay CR 
signals to ultimately change DME and DT expression.  The above 
observations also indicate that the inability of CR to reverse certain DME 
and DT changes may indicate towards altered disposition and 
pharmacokinetics of metabolites and xenobiotics.   
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FIGURES LEGENDS 
FIGURE II-1: Effect of 40% kCAL reduced calorie diet in WT (C57Bl/6) 
and Lepob/ob (OB) mice.  (A) Decreased body weight and percent body 
weight in WT and OB mice after CR.  During 10 weeks of 40% reduced 
caloric diet (CR), body weight of ad libitum fed (n=7) and CR (n=10) mice 
(both WT and OB) was determined every week.  The percent body weight 
changes were calculated with the body weight at initial time point 
considered as 100% and each mouse being its own control.   The data is 
represented as average ± SEM (n=7 for controls and n=10 for CR) body 
weight or percent body weight change over the weeks of CR.  (B) 
Morphological changes in livers of WT and OB mice upon CR.  Adult WT 
and OB mice either fed ad libitum (n=7) or 40% reduced caloric diet (CR) 
(n=10) for 10 weeks.  Livers were collected, fixed in 10% buffered formalin, 
paraffin embedded, sectioned, and stained with hematoxylin and Eosin.  (C) 
Induction of Pgc-1α, pepck, Pparα, Car and downregulation of Srebp-1 
mRNA expression in mouse liver after 10 weeks CR.  Total RNA was 
isolated from livers of ad libitum (AL) fed controls and mice undergoing CR 
and gene expression of Pgc-1α, pepck, Pparα, Car and Srebp-1 was 
quantified by Branched DNA signal amplification assay (Quantigene 1.0 
assay), obtained from Affymetrix Inc., CA, USA.  The data is represented as 
average ± SEM (n=7 for AL and n=10 for CR) fold change over the fed 
controls.  P<0.05 was considered statistically significant. Groups without a 
common letter are significantly different. (D) Effect of CR on hepatic 
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glutathione levels in WT and OB mice.  Hepatic glutathione levels were 
measured in livers of WT and OB AL and CR mice using the GSH-Glo™ kit 
(Promega Corp., MD, USA) according to manufacturer’s protocol.  The data 
is represented as average ± SEM (n=7 for AL and n=10 for CR) uM GSH / 
mg liver weight.  P<0.05 was considered statistically significant. Groups 
without a common letter are significantly different.    
 
FIGURE II-2:  Effect of CR on expression of certain Phase I and II 
metabolizing enzymes in WT and OB mouse livers. (A) Changes in 
expression of Phase I metabolizing enzymes in WT and OB mouse 
livers upon CR. Total RNA was isolated from livers of ad libitum (AL) fed 
controls and mice undergoing CR and gene expression of Cyp2b10, 
Cyp3a11, Cyp4a14, Cyp7a1, Cyp7b1 was quantified by Branched DNA 
signal amplification assay (Quantigene 1.0 assay), obtained from Affymetrix 
Inc., CA, USA.  The data is represented as average ± SEM (n=7 for AL and 
n=10 for CR) fold change over the fed controls.  P<0.05 was considered 
statistically significant. Groups without a common letter are significantly 
different.  (B) Changes in expression of Phase II metabolizing enzymes 
in WT and OB mouse livers upon CR. Total RNA was isolated from livers 
of ad libitum (AL) fed controls and mice undergoing CR and gene 
expression of Gclc, Gsta-1, Ho1, Nqo1, Sod1 was quantified by Branched 
DNA signal amplification assay (Quantigene 1.0 assay), obtained from 
Affymetrix Inc., CA, USA.  The data is represented as average ± SEM (n=7 
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for AL and n=10 for CR) fold change over the fed controls.  P<0.05 was 
considered statistically significant. Groups without a common letter are 
significantly different 
 
FIGURE II-3: Effect of CR on liver uptake transporter (A) mRNA and (B) 
protein expression in WT and OB mice. Total RNA was isolated from 
livers of ad libitum (AL) fed controls and mice undergoing CR and gene 
expression of Oatp1a1, Oatp1a4 and Oatp1b2  was quantified by Branched 
DNA signal amplification assay (Quantigene 1.0 assay), obtained from 
Affymetrix Inc., CA, USA.  The data is represented as average ± SEM (n=7 
for AL and n=10 for CR) fold change over the fed controls.  P<0.05 was 
considered statistically significant. Groups without a common letter are 
significantly different.  Membrane proteins were isolated from livers of AL 
and CR WT and OB mice.  Protein expression of Oatp1a1, Oatp1b2 was 
quantified by western blotting.  The data is representative of three individual 
protein quantifications. 
 
FIGURE II-4:  Effect of CR on liver efflux transporters mRNA and 
protein expression in WT and OB mice. Total RNA was isolated from 
livers of ad libitum (AL) fed controls and mice undergoing CR and gene 
expression of Abcb4, Abcb11, Abcc1-6, Abcg2 was quantified by Branched 
DNA signal amplification assay (Quantigene 1.0 assay), obtained from 
Affymetrix Inc., CA, USA.  The data is represented as average ± SEM (n=7 
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for AL and n=10 for CR) fold change over the fed controls.  P<0.05 was 
considered statistically significant. Groups without a common letter are 
significantly different.  Membrane proteins were isolated from livers of AL 
and CR WT and OB mice.  Protein expression of Abcc2-4 and Abcg2 was 
quantified by western blotting.  The data is representative of three individual 
protein quantifications. 
 
FIGURE II-5: Effect of CR on (A) transcription factor activity and (B) 
relative expression patterns of prototypical target genes of 
transcription factors in livers of WT and OB mice . (A) CR changes the 
transcription factor binding activity in livers of WT and OB mice. Liver 
nuclear extracts were prepared from control and fasted WT and obese mice 
using Procarta TF nuclear extraction kit and analysis for Ahr, Creb, Fxr, 
Nrf2 and PXr binding was determined using a 9 plex Procarta TF binding 
assay.  The data is represented as average ± SEM (n=7 for AL and n=10 
for CR) fold change over the fed controls.  P<0.05 was considered 
statistically significant. Groups without a common letter are significantly 
different.  (B) CR differentially affects expression of prototypical target 
genes of transcription factors in WT and OB mouse livers.  Heatmaps 
were created for visual pattern analysis of Cyp2b10, Cyp3a11, Cyp4a14, 
Cyp7a1, Oatp1a1,Oatp1a4, Abcc1-6, Abcg2, Nqo1, Ho1, Gclc, Gcta1, Sod1 
in both WT and OB livers upon CR using R statistical software.  The gene 
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expression was analysed as fold change of WT and OB CR mice over 
respective AL groups.   
 
FIGURE II-6: Effect of AMPK pathway activation on transcription factor 
expression in WT and OB hepatocytes. (A) mRNA quantification of 
transcription factor expression. Primary hepatocytes were obtained from 
(male, 11 weeks old) WT and OB mouse livers.  Primary mouse 
hepatocytes were treated with control, AICAR (0.5mM), NAD+ (5mM) or 
metformin (1mM) for 6 hours.  Total RNA was isolated 6 hours after 
treatment and mRNA expression of  Car, Fxr, Nrf2, and Pxr  was quantified 
using real time quantitative PCR.  The data is represented as average ± 
SEM (n=3) fold change over the fed controls.  All data is normalized to 18S 
rRNA. Groups without a common letter are significantly different. (B) AMPK 
activators differentially alter mRNA expression of various 
transcription factors in WT and OB mice. Heatmaps were created for 
visual pattern analysis of Nqo1, Gclc, Abcc2, Abcc3, Nrf2, Car, Pxr and Fxr  
in both WT and OB livers upon CR using R statistical software.  The gene 
expression was analysed as fold change of WT and OB CR mice over 
respective AL groups.   
 
FIGURE II-7: Activation of CR pathways in part reverses drug 
metabolizing enzyme and transporter changes caused due to 
steatosis.  Caloric restriction via activation of AMPK pathway alters 
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expression and activity of Car, Nrf2, Fxr while Pxr activity remains 
unaffected.  These changes in transcription factor activity changes the 
expression of various Phase I and II biotransformation enzymes and 
transporters.  Steatotic liver demonstrates an altered transcription factor 
activity which upon CR is only partly reversed as seen in B. 
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FIGURE II-1: 
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FIGURE II-2: 
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FIGURE II-3: 
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FIGURE II-4: 
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FIGURE II-5: 
 
 
 
 
 
 
 
 111 
 
 FIGURE II-6: 
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FIGURE II-7: 
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TABLES 
 
TABLE II-1: Effect of CR on body weight, liver-to-body weight ratios 
and biochemical profile:  Adult C57Bl/6 and ob/ob mice (n=7-10/group) 
were fed (ad libitum) or put on 40% reduced caloric diet for 9 weeks.  At the 
end of 9 weeks, mice were euthanized.  Average liver weights, liver-to-body 
weight ratios, serum glucose (mg/dl), serum and liver triglycerides (mg/dl) 
and serum NEFA (mmol/dl) were determined. P<0.05 was considered 
statistically significant. Groups without a common letter are significantly 
different. 
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TABLE II-2: Effect of CR on serum metabolic hormones:  Adult C57Bl/6 
and ob/ob mice (n=7-10/group) were fed (ad libitum) or put on 40% reduced 
caloric diet for 9 weeks.  At the end of 9 weeks, mice were euthanized.  
Average serum leptin, glucagon, resistin, and insulin levels  were 
determined. P<0.05 was considered statistically significant. Groups without 
a common letter are significantly different. 
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ABSTRACT 
Studies demonstrate that changes in miRNA expression alter etiology and 
development of steatosis.  CR reverses steatosis by increase in fatty acid 
oxidation genes such as Pparα, Cpt1a via activation of Sirt1/Pgc-1α 
cascade while downregulating expression of lipogenic master regulators 
Srebp1c, Pparγ and their target genes.  Nuclear factor E2-related factor 2 
(Nrf2)/Kelch like ECH associated Protein 1 (Keap1) pathway is a key 
antioxidant gene regulatory pathway with altered activity in steatotic 
conditions.  However, very little is known about the interactions of 
Nrf2/Keap1 and CR activated pathways.  The purpose of this study was to 
determine the effect of Nrf2/Keap1 pathway on expression of miRNAs 
important in regulating lipid metabolic genes upon CR.  Keap1 WT and KD 
mice were maintained on 40%CR for 6 weeks and the lipid metabolic gene 
expression (Pparα, Cpt1a, Pgc1α, Sirt1 and Srebp1c, Fas, Acc1) were 
quantified.  Keap1 knockdown enhanced the effect of CR on induction of 
fatty acid oxidation genes while increasing fold inhibition of lipid synthetic 
genes.  miRNA 34a, 370, let-7b, 144, 221 were significantly affected by 
alteration in Nrf2/Keap1 pathway activity as well as CR.  Thus, the data 
presented in this study indicate an important regulatory role of Nrf2/Keap1 
pathway in miRNA expression as well as potential novel mechanism for the 
differential effect of CR in Keap-1KD mice. 
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INTRODUCTION 
Small non-coding RNAs, microRNAs have been recently demonstrated to 
provide an additional layer of regulatory control in development, 
homeostasis and pathology (1).  microRNAs, 19-22 nucleotides long, act as 
gene silencers with the RNA induced silencing complex (RISC) and 
modestly regulate gene expression (2).  Mammalian microRNAs do not 
necessarily exhibit complete homology with the target mRNA and along 
with classically known cleavage of target mRNA, they can also affect mRNA 
stability (1).  Due to partial homology, a single miRNA is shown to regulate 
expression of multiple target mRNAs (3).  miRNA expression and activity is 
altered in various disease conditions including metabolic syndrome (4).  
miRNA expression and regulation are being explored in detail as potential 
targets and possible biomarkers in various diseases, specifically metabolic 
syndrome and cancer (5, 6).   
Non alcoholic fatty liver disease (NAFLD) is referred to as the 
hepatic manifestation of metabolic syndrome (7, 8) and encompasses 
various conditions of fat deposition and inflammation of the liver.  Steatosis 
or fatty liver comprises of excessive accumulation of fat in the hepatocytes.  
Prevalence of NAFLD is estimated to be between 3.1% and 16.4% among 
adults, respectively (9, 10), known to afflict obese and normal weight 
persons and children as well with consequences such as altered 
pharmacokinetics of xenobiotics and endogenous metabolites, drug 
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induced liver injury (DILI) and propagation of insulin resistance complicating 
metabolic syndrome.   
Through various in vitro and in vivo studies, miRNA have been 
shown to alter etiology and development of steatosis.  miR122 has been 
shown to be involved in regulation of cholesterol and triglyceride synthesis, 
silencing miR122 drastically decreased cholesterol synthesis, decreased 
fatty acid levels and triglyceride load on the liver in mice fed a high fat diet 
(11, 12).  Patients with NAFLD demonstrated increased circulating miR122 
levels along with miR34a (13).  miR34a is another miRNA that has been 
shown to regulate important aspects of fatty acid oxidation via silencing 
Sirtuin1 (Sirt1), a master regulator of energy homeostasis in the cell (14).  
Sirt1 is known to inhibit miR34a via histone deacetylation, while positively 
upregulating FXR expression (15).  miR33a has been shown to be 
important for its regulation of Srebp expression and hence steatotic 
development (16, 17).  miR221 has been demonstrated to be important in 
development of liver fibrosis and hepatocellular carcinoma (18).  Let7 
miRNA increases insulin resistance via modulating insulin receptor (InsR) 
expression along with glut4 expression in skeletal muscle (19, 20).  
Knockdown of Let-7 miRNA prevented ectopic fat deposition in liver along 
with build up of adipose tissue in mice on a high fat diet (21).     
 
American Association for Study of Liver Disease (AASLD) 
recommends caloric restriction and exercise to reverse steatosis/fat load on 
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the liver .  Beneficial effects of CR are attributed to activation of Sirt1 which 
activates gluconeogenic and fatty acid oxidation genes expression via 
coactivator; Peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (Pgc-1α) (22, 23).  Sirt1 activates the nuclear receptor Pparα via 
acetylation of Pparα coactivator (Pgc1-α) and upregulation of fatty acid 
oxidation genes such as Cpt1a (24, 25).  At the same time CR activation of 
Sirt1/Pgc-
such as Srebp1c, Lxr and their target genes Fas, Acc1, Acot1, Fabp4, 
Scd1.   
Among various transcription factors altered in steatosis, Nuclear 
factor E2-Related factor 2 (Nrf2) pathway has been shown to be increased 
in mouse and human models of NAFLD.  Nrf2 belongs to the basic leucine 
zipper family of transcription factors, tethered into the cytoplasm via a 
complex with Kelch like ECH-associated Protein 1 (Keap1), which upon 
activation translocates to the nucleus and activates gene transcription (26, 
27).  Nrf2 is an important transcription factor known for its role in xenobiotic 
metabolism and oxidative stress response (28, 29).  Nrf2 regulates 
expression of genes important in metabolism and oxidative stress response 
such as (Nqo1), Heme Oxygenase (HO-1) and Glutathione S-Transferase 
(30).  Nrf2 acts via inhibition of LXRα dependant increases in Srebp1 
expression and thus decreased lipogenesis (31).  Shin et al., 2009 and 
Tanaka et al., 2008 demonstrated increased hepatic lipid accumulation in 
absence of Nrf2 in mice basally or upon high fat diet feeding (32, 33).   
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More recently, studies also identify Nrf2 as a positive regulator of lipogenic 
genes such as Pparγ, Scd-1, Srebp1, Cebpβ, basally or upon exposure to 
high fat diet (34-36).  Recent studies by Xu et al,. 2012 demonstrates an 
increased expression and activity of Nrf2 in leptin deficient obese mice (37).  
Despite being controversial, evidence points towards an important role for 
Nrf2 in either ameliorating or exacerbating steatosis.   
Recent studies have demonstrated that anti-carcinogenic, protective 
activity of Nrf2 in models of caloric restriction (38).  However, no studies 
determine the effect of caloric restriction on Nrf2 and its target gene 
expression.  Furthermore, no studies present an account of effect of altered 
Nrf2 activity and susceptibility to CR.  No studies outline whether CR 
induced fatty acid oxidation and diminished lipogenesis involves a change 
in Nrf2 activity.   
In the present study, we demonstrate differential susceptibility of a 
mouse model, constitutively overexpressing Nrf2 (Keap1-KD mice) to CR.  
We attribute these changes to novel changes in the miRNA regulatory 
circuit.  We demonstrate that the enhanced susceptibility to CR in Nrf2 
overexpressing mice could be partly associated with differential changes in 
miRNA expression, especially those known to be involved in regulation of 
lipogenic as well as fatty acid oxidation genes.  We present novel data 
potentially indicating an important regulatory role for Nrf2-Keap1 pathway in 
small RNA expression. 
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MATERIALS AND METHODS: 
Animals and treatments:  Keap1-KD mice were obtained from laboratory 
of Dr.Curtis Klaassen at the Kansas University Medical Center,Kansas, 
USA bred at the animal facility in Fogarty Hall, University of Rhode Island.  
The average caloric consumption were calculated for each mouse on a 
purified diet (AIN93-G) obtained from Testdiet, IN,USA over a period of 10 
days.  C57Bl/6 and Keap-1KD mice (16 weeks age) were each divided into 
2 groups of n=5 and n=6.  One group of each genotype (n=5) was 
maintained as a control group which was fed ad libitum (AL) over the length 
of the experiment.  The other group of each phenotype (n=6) was put on a 
40% reduced caloric diet (CR) for a period of 10 weeks with ad libitum 
access to water.  Body weight and food consumption was monitored at 
least weekly throughout the study.  The study was terminated when weight 
loss plateau was reached (After 7 weeks CR).  Mice were sacrificed; blood 
and livers were collected.  Livers were snap frozen in liquid nitrogen and 
stored in -80°C until further analysis.  Serum glucose (Cayman Chemicals, 
Ann Arbor, MI), serum and liver triglyceride (Pointe scientific, MI, USA) and 
free fatty acid concentrations (Wako diagnostics, VA) were determined by 
spectrophometeric assay kits.  
 
RNA Isolation and mRNA Quantification: Total RNA was isolated from 
the collected livers by phenol-chloroform extraction with RNAzol B reagent 
(Tel-Test Inc., Friendswood, TX) according to the manufacturer’s 
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instructions.  RNA concentration was determined by measuring UV 
absorbance at 260 nm using NanoDrop™ and the integrity were confirmed 
by formaldehyde gel electrophoresis.   mRNA expression was quantified by 
RT2-PCR, with expression normalized to 18S rRNA expression.  
miRNA quantification: Total RNA enriched for small nucleotide fraction 
was isolated from livers obtained from AL and CR C57Bl/6 and Keap1-KD 
mice using the miRNA easy mini kit (Qiagen Inc, MD, USA).  1µg total RNA 
was used for miRNA cDNA preparation using RT2 miRNA first strand kit 
(Qiagen Inc, MD, USA) and miR34a, miR370, miR122, miR221, miR144 
expression was measured by by RT2-PCR.  The miRNA expression was 
normalized to mean expression levels of Snord65, Snord66 and Snord85. 
 
Tissue homogenate preparation: Liver tissue homogenate was obtained 
by homogenization with RIPA (Tris 50mM, NaCl 150 mM, SDS 0.1 % and 
TritonX-100 1.0%) and short centrifugation to remove the debris.  The 
protein concentration of the samples will be measured according to the 
manufacturer’s instruction using BCA protein assay (Thermo Fisher 
Scientific, Rockford, IL, USA).   
 
Western Blotting:  Proteins in the obtained membrane preparations will be 
solubilized in Laemmli buffer and β-mercaptoethanol and electrophoretically 
separated on a tris-polyacrylamide gel (10% for Sirt1 and Fas) at 200V for 
50 min and transferred onto a PVDF membrane at 100V for 30-45 min or at 
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75V for 1.5 hours. The membrane will be blocked overnight with 2% Non fat 
dry milk (NFDM) in phosphate buffered saline with 0.05% Tween 20 (PBS/T 
or TBS/T).  After blocking, the membrane will be incubated with appropriate 
concentrations of primary antibodies diluted in 2%NFDM in PBS/T or TBS/T 
for 2 hours and subsequently with corresponding horseradish peroxidase 
labeled secondary antibodies also diluted in 2%NFDM in PBS/T or TBS/T.  
The blots will then be incubated in ECL-Plus western blot detection reagent 
and the blots will be exposed on X-ray films.  The blots will be quantified 
using ImageQuant software.  Results obtained will be tested for statistical 
significance. 
miRNA array analysis:  PCR arrays (mouse genome V2.0) 
(SABiosciences, Frederick, MD,USA) were used to determine expression of 
miRNA in pooled liver RNA samples isolated using miRNA easy kit 
(Invitrogen Corp, MD, USA) as per manufacturers instructions.  Data 
analysis was performed with the web-based software package for the 
miRNA PCR array system. 
(http://www.sabiosciences.com/pcr/arrayanalysis.php). 
 
Statistics: The statistical significance of differences will be determined by 
Duncan’s factorial ANOVA test or a standard student T-test.  P<0.05 will be 
considered statistically significant. Groups without a common letter will be 
considered significantly different. 
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RESULTS 
Constitutive overexpression of Nrf2 enhances susceptibility to weight 
loss and fat mobilization upon CR:  To determine whether constitutive 
overexpression of Nrf2 changes susceptibility to weight loss and fat 
mobilization, C57Bl/6 and Keap1-KD mice were either fed ad libitum or out 
on 40%CR for 6 weeks.  As seen in Fig. 1A, Keap1-KD mice fed ad libitum 
gained less weight over time than the C57Bl/6 counterparts.  While C57Bl/6 
mice fed ad libitum gained approximately 15% of their initial weight at the 
end of the study, Keap-1 KD mice gained significantly lower percentage 
(8%) of their initial weight at the starting point (week0) (Fig. 1A).    Upon 
CR, both C57Bl/6 and Keap1-KD mice lost approximately 43% of their initial 
weight (Fig. 1A).   
 
Caloric restriction increases expression of fatty acid oxidation genes 
to a higher fold in Keap1-KD mouse livers- To identify whether the 
hallmark fatty acid oxidation genes are activated upon CR, mRNA 
expression of Sirt1, Pgc1α, Ppar α was quantified along with Cpt1a.  
Basally, Keap1KD mouse livers demonstrated an elevated expression of 
Cpt1a and Ppar α over the C57Bl/6 controls (Fig. 2A).  As observed in 
Fig.2A, CR restriction induced the expression of Sirt1, Pgc1 α, Ppar α in 
livers of both C57Bl/6 and Keap1-KD mice.  The induction of Pgc1α, Pparα 
was the highest in livers of Keap1-KD mice which were calorically restricted 
(Fig. 2A) presenting a novel observation and potentially an effect of Keap1 
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knockdown increasing the inducibility of the Sirt1/Pgc1α cascade in these 
livers. 
 
Constitutive overexpression of Nrf2 increases CR induced 
downregulation of lipogenic gene expression in mouse livers- CR is 
known to classically down regulate the expression of gene involved in 
biosynthesis of fats.  Hence, mRNA expression of genes such as Srebp1c, 
Lxr and the target genes such as Fas, Acc1, Fabp4 and Scd1.  As seen 
from Fig. 2B, in C57Bl/6 mice, CR downregulated expression of lipogenic 
gene expression regulators, Srebp1c Lxr to ~50% of the ad libitum fed 
controls.  Target genes regulated by these transcription factors such as, 
Fas, Fabp4, Acc1 were also downregulated significantly over the fed 
controls (Fig. 2B).  Basal expression of some of the lipogenic genes such 
as Acc1, Fab4, Fas and Scd1 was lower in the Keap1-KD mice as 
compared to ad libitum fed C57Bl/6 mice (Fig.2B).  Upon CR, the 
expression of these lipogenic genes was not altered in Keap1-KD mice, 
even though the gene downregulation of the regulatory Srebp1c was 
significantly lower in the Keap1-KD mouse livers over the calorically 
restricted C57Bl/6 mice (Fig. 2B). 
   
Keap1-KD enhances the effect of caloric restriction on Nrf2 target 
gene expression- To determine whether CR has an effect of Nrf2 target 
gene expression, we quantified the mRNA expression of Nrf2 and its target 
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genes Nqo1 and Gclc in C57Bl/6 and Keap1-KD mice on CR.  As seen in 
Fig. 2C, CR induces expression of Nqo1 (~1.6 fold) and downregulates the 
expression of Nrf2 and Gclc (~30% and 79% respectively) in C57Bl/6 mice.  
Basal expression of Nrf2 target genes, Nqo1 and Gclc was significantly 
higher in Keap1-KD mouse livers, which is consistent with previous 
publications (39).  Absence of Keap1 did not significantly alter the effect of 
CR on Nrf2 mRNA expression (~69% downregulation over the ad libitum 
Keap1-KD controls).  However, knockdown of Keap1 significantly enhanced 
the effect of CR on downregulation of Gclc (80% in C57Bl/6 CR versus 60% 
in Keap1-KD CR mouse livers) and induction of Nqo1 (~1.6 fold in C57Bl/6 
CR versus 1.4 fold in Keap1-KD CR mouse livers) (Fig. 2C). 
 
Caloric restriction significantly alters expression of miRNA important 
in regulating fatty acid oxidation and lipogenic genes-  To determine if 
the induction of fatty acid oxidation genes upon CR is dependent upon 
altered levels of miRNA regulatory circuit, miRNA expression of various 
miRNAs found in the mouse genome were quantified in Keap-1 WT CR and 
Keap1-KD CR pooled samples.  CR differentially regulated the expression 
of miRNAs as shown in Table 1A and 1B. 
Working on the observation further, miR34a, miR370, let-7b, miR122 and 
miR221 was quantified.  As seen in Fig.3A, Keap1 knockdown significantly 
decreased basal expression of miR34a, miR370 and let-7b.  This 
observation is consistent with the higher basal expression of Cpt1a and 
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Pparα (Fig. 2B).  Caloric restriction significantly decreases expression of 
miR34a, let7b and miR144 in C57Bl/6 mouse livers (Fig. 3A).  Keap1-KD 
did not significantly affect the decrease in miR144 expression upon CR, 
while it enhanced the decrease in expression of miR34a (Fig. 3A).  On the 
other hand, CR resulted in downregulation of miR370 in Keap1-KD mouse 
livers while it remained unchanged in C57Bl/6 mice.  On the other hand CR 
decreased let7b expression in C57Bl/6 mice while remaining unchanged in 
Keap1-KD mice (Fig. 3A).   
 
Knockout of Nrf2 reverses basal miRNA expression pattern changes 
in mouse liver - To determine whether basal miRNA expression changes 
were due to a change in Nrf2 expression in the Keap1-KD mouse model, 
miRNA expression was quantified in Nrf2 KO male mice put on 40% caloric 
restriction.  As seen in Fig. 3B, Nrf2 KO mice showed a reversal of basal 
expression changes as compared to Keap1-KD mice.  miR34a and let7b 
while being downregulated in Keap1-KD mice, remained unchanged basally 
(Fig. 3B), whereas miR144 and miR221 demonstrated an opposite basal 
expression pattern in Nrf2 KO and Keap1-KD mice as compared to C57Bl/6 
mice.  miR370 however, was significantly downregulated in both Nrf2 KO 
mice as well as Keap1-KD mice, with a higher fold downregulation in the 
Nrf2 Kos (Fig.3B).  CR in this cohort of mice did not alter miR 34a, let7b 
expression (Fig. 3B) while miR221 was induced by ~3 fold.  CR however, 
increased the expression of miR34a, miR144 and miR221 in Nrf2 KO 
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mouse livers, while in Keap1-KD mice their expression was either 
decreased (miR34a, miR144) or remained unchanged (miR221).  These 
observations indicate towards as novel role of Nrf2 as well as Keap1 in 
regulating expression of miRNAs important in lipid metabolism as well as a 
differential effect of CR in Keap1-KD versus Nrf2 KO mice.   
 
Caloric restriction decreases expression of certain RISC complex 
genes- Differences in the expression of RISC complex components along 
with miRNAs could also affect target mRNA gene expression in Keap1-KD 
mice and potentially explain the basal level differences in expression of 
certain genes in these mice.  Hence, mRNA expression of RISC complex 
components such as Dicer, Drosha, exportin 5 was determined by RT2-
PCR.  Although no significant differences were observed in basal 
expression of these genes in Keap1-KD mouse livers as compared to 
C57Bl/6 controls, the effect of CR was different in each genotype.  As seen 
in Fig. 4, CR decreased expression of Exportin5 and Drosha in C57Bl/6 
mice.  RISC complex factors in Keap1-KD mice on the other hand remained 
unchanged upon CR (Fig. 4), indicating a potential role for Keap1 in 
regulating CR dependent changes in RISC complex factor expression. 
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DISCUSSION 
There has been an increase in the number of studies focusing on the 
miRNA regulatory pathways as potential gene therapy candidates and 
biomarkers for pathological conditions such as diabetes, cancer, NAFLD 
(40).  The purpose of this study was to identify whether constitutive over 
expression of Nrf2 by knockdown of Keap1, changes the effect of caloric 
restriction (CR) on expression of fatty acid oxidation and lipogenic genes.  
This study also aims at identifying whether CR alters expression changes 
expression of miRNAs that have been demonstrated to regulate the 
expression of lipid metabolic and biosynthetic genes.   This study presents 
novel data about presence or absence of Nrf2 and Keap1 changing miRNA 
expression, and how these changes cause a differential effect of CR has 
also been studied. 
Epigenetic regulation has emerged as an important contributor to 
downstream effects of CR.  Preliminary studies have demonstrated that CR 
intervention causes DNA methylation changes at loci of gene important in 
insulin signaling and weight control in human adipose tissue (41) and these 
changes are being considered for biomarker studies during weight loss 
(42).  Other studies have demonstrated a change in DNA methylation 
machinery such as DNA methyl transferases (dnmt3a) and methylation on 
oncogenes such as p53 and H-Ras (43).  CR has also been shown to 
change histone acetylation (44) via changes in expression of histone acetyl 
transferases and histone deacetylases, specifically Sirt-1 models in vitro 
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and in vivo.  Scant but convincing data demonstrates the importance of 
miRNA regulation in effects of CR.  Hence, it is important to address the 
regulatory role of Nrf2-Keap1 pathway in basal and CR induced changes 
miRNA expression and downstream alterations in lipid metabolic genes.   
The effect of miRNA expression in the current study can be divided into two 
parts: miRNAs basally altered by both Keap1 and Nrf2 knockdown as well 
as CR (miR34a, miR370, Let-7b*, miR221); miRNAs altered only by CR 
(miR144).  As observed from results obtained in this study, CR effects the 
expression of miR34a, miR370, miR 122, Let7-b in mouse livers.  miR34a 
known to regulate and be regulated by Sirt1(15), is down regulated upon 
CR in WT mouse livers corresponding to an increase in Sirt1 mRNA 
expression along with Pgc-1α.  As observed miR34a expression is lower in 
Keap-1KD livers to begin with (Fig. 3A) and decreases further upon CR with 
a correspondingly higher increase in Sirt1 and Pgc-1α mRNA expression.  
On the other hand, CR increases miR34a expression in Nrf2 null mouse 
livers indicating and important effect of Nrf2 on regulating miR34a 
expression upon activation of CR pathways such as AMPKinase pathway 
(45).  These results indicate an important effect of Keap1 knockdown as 
well as absence of Nrf2 on the regulation of miR34a expression and hence, 
potentially Sirt1 and Pgc-1α expression.  Similarly, Keap1 knockdown 
basally decreased expression of miR370 and let-7b*.  miR370 is known to 
target the 3’UTR of Cpt1a (46) and decrease fatty acid oxidation while 
increasing triglyceride build up.  In the same study, a dominant negative 
 132 
 
form of c-jun increased miR370 expression along with Srebp1c mRNA 
expression while decreasing Cpt1a mRNA expression, a pattern which is 
opposite to the observations made in the Keap1 knockdown livers in this 
study.  This potentially indicates towards a positive correlation between c-
Jun and Keap1.  Nrf2 null mouse livers however, do not demonstrate an 
increase in miR370 expression, which indicates towards the importance of 
Keap1 and not Nrf2 in miR370 regulation.   It has been indicated that Keap1 
and c-Jun act as negative regulators of Nrf2 activity (47), thus indicating 
that Keap1 and c-Jun directly or indirectly via Nrf2 regulate the expression 
of miR370 and by association, miR122 (46).  Let-7 family of miRNAs is 
known to affect the expression of genes insulin pathway such as insulin 
receptor and Glut4.  Let-7 family also enhances the expression of 
hemoxygenase-1 (HO-1) an important Nrf2-Keap1 target gene important in 
anti-oxidant response by inhibiting Bach1 repressor in vitro (48).  In this 
study, let-7b* expression is down regulated in Keap1-KD mice while it 
remains unaffected in Nrf2 null mice basally.  These preliminary 
observations imply a potential negative feedback regulation of Let-7b 
expression by Nrf2 or simply a negative regulatory effect of Nrf2.  CR did 
not alter the expression of Let7b in Keap1-KD as well as Nrf2 null mice 
indicating a Nrf2-Keap1 independent mechanism of Let-7b regulation by 
CR.     
miR144 is downregulated by CR.  Increased miR144 is associated with 
oxidative stress in red blood cells (49) and a decreased Nrf2 expression 
 133 
 
and activity.  Basally, miR144 was downregulated in Keap1-KD mouse 
livers over wild types while being increased in expression in the Nrf2 null 
mouse livers (Fig. 3B).  In line with these observations, Nqo1 expression 
increases in Keap1-KD mouse livers basally and higher upon CR (Fig. 2C).  
These preliminary observations indicate a potential negative, inhibitory 
regulatory action of Nrf2 on miR144 expression.   
The outcome of Keap-1 KD on effect of CR primarily indicates towards a 
higher efficiency of Keap-1KD mice in weight loss and fatty acid oxidation 
over the wild types.  The miRNA regulatory circuit is differentially expressed 
in moouse models of decreased Keap1 or Nrf2 activity along with a 
differential effect of CR on either genotype.  Increasing evidence suggests 
an important regulatory role of Keap1-Nrf2 pathway in development and 
progression of steatosis, obesity-diabetes and metabolic syndrome 
associated adverse outcomes. 
A novel observation is the effect of CR on the miRNA processing complex 
as well as the upstream processors of miRNA processing such as the RISC 
complex.  Basal expression of the components was not affected by Keap-1 
knockdown.  CR decreased the expression of drosha and exportin5 in 
control mice while remaining unchanged in Keap1-KD mice.  These 
preliminary observations indicate absence of Keap-1or increased 
abundance of Nrf2 as a regulator of RISC complex components.  One study 
has published a decrease in dicer expression upon aging (50), making mice 
more susceptible to oxidative stress.  Keap1-KD mice do show an 
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increasing trend in expression of these RISC components which might 
explain the ability of Keap-1KD mice to antagonize oxidative stress better 
via increased expression of Nrf2 target genes and a decreased expression 
of miRNAs regulating their expression, such as miR144.        
With miRNA gene therapy being investigated as potential treatments to 
alleviate metabolic syndrome, the miRNAs effecting and affected by the 
Nrf2-Keap1 regulatory pathway potentially represent important targets for 
further investigation.     
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FIGURE LEGENDS: 
FIGURE III-1: Keap-1KD mice are gain less weight on purified rodent 
diet and are more susceptible to weight loss upon CR as compared to 
C57Bl/6 mice.  (A) Decreased body weight and percent body weight in 
Keap1 WT and Keap1-KD mice after CR.  During 6 weeks of 40% reduced 
caloric diet (CR), body weight of ad libitum fed (n=5) and CR (n=5) mice 
(both WT and OB) was determined every week.  The percent body weight 
changes were calculated with the body weight at initial time point 
considered as 100% and each mouse being its own control.   The data is 
represented as average ± SEM (n=5) body weight or percent body weight 
change over the weeks of CR.  (D) Effect of CR on serum glucose, 
triglycerides and free fatty acid levels in Keap WT and Keap1-KD mice 
during active weight loss.  Serum glucose, triglyceride and free fatty acid 
levels were quantified from Keap1 WT and Keap1-KD mice, 3 weeks into 
40% CR.  Blood was collected by cheek pouch bleed, serum isolated and 
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used for quantification.  The data is represented as average ± SEM (n=5) 
fold change in serum biochemical factors over the ad libitum fed controls.  
P<0.05 was considered statistically significant. Groups without a common 
letter are significantly different. 
 
FIGURE III-2: Keap1 knockdown enhances the activation of fatty acid 
oxidation genes and inhibition of lipogenic genes upon CR: (A) Effect 
of CR on fatty acid oxidation gene expression in Keap1 WT and Keap1-KD 
mouse liver:  After 6 weeks of 40% reduced caloric diet (CR), total RNA 
was isolated from ad libitum and CR Keap1 WT and Keap1-KD mouse 
livers.  mRNA expression of Sirt1, Pparα, Cpt1a, Acot1 and Pgc-1αwas 
quantified by RT2-PCR.  The data is represented as average ± SEM (n=5) 
fold changes in expression over the controls.  (B) Effect of CR on lipogenic 
gene expression in Keap1 WT and Keap1-KD mouse liver:  After 6 weeks 
of 40% reduced caloric diet (CR), total RNA was isolated from ad libitum 
and CR Keap1 WT and Keap1-KD mouse livers.  mRNA expression of 
Srebp1c, Lxr, Fas, Acc1, Scd1 was quantified by RT2-PCR.  The data is 
represented as average ± SEM (n=5) fold changes in expression over the 
controls.  (C)   Effect of CR on Nrf2 target gene expression in Keap1 WT 
and Keap1-KD mouse liver:  After 6 weeks of 40% reduced caloric diet 
(CR), total RNA was isolated from ad libitum and CR Keap1 WT and 
Keap1-KD mouse livers.  mRNA expression of Nqo1, Gclc and Nrf2 was 
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quantified by RT2-PCR.  The data is represented as average ± SEM (n=5) 
fold changes in expression over the controls.  
 
FIGURE III-3:  Effect of constitutive over-expression and knockdown 
of Nrf2 on miRNA expression in mouse livers upon CR: (A) Effect of CR 
on miRNA expression in livers of Keap1 WT and Keap1-KD mouse livers: 
RNA fraction enriched for small RNAs was isolated from livers of ad libitum 
fed and 40% CR, Keap1 WT and KD and miRNA expression of miR34a, 
miR370, Let-7b, miR144, miR221 and miR122 was quantified by RT2-PCR.  
The data is represented as average ± SEM (n=4) fold changes in 
expression over the controls. (B) Effect of CR on miRNA expression in 
livers of Nrf2 WT and Nrf2 null mouse livers: Small RNA fraction enriched 
for small RNAs was isolated from livers of ad libitum fed and 40% CR, Nrf2 
WT and Nrf2 null and miRNA expression of miR34a, miR370, Let-7b, 
miR144, miR221 and miR122 was quantified by RT2-PCR.  The data is 
represented as average ± SEM (n=4) fold changes in expression over the 
controls.  
 
FIGURE III-4:  Effect of constitutive over-expression and knockdown 
of Nrf2 on RISC complex component expression in mouse livers upon 
CR:  After 6 weeks of 40% reduced caloric diet (CR), total RNA was 
isolated from ad libitum and CR Keap1 WT and Keap1-KD mouse livers.  
mRNA expression of Dicer, Exportin 5 and Drosha was quantified by RT2-
 146 
 
PCR.  The data is represented as average ± SEM (n=5) fold changes in 
expression over the controls. 
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TABLES: 
TABLE III-1: Differential (A) increase and (B) decrease in expression of 
miRNAs in livers of C57Bl/6 and Keap1-KD mice upon CR: RNA fraction 
enriched for small RNAs was isolated from livers of ad libitum fed and 40% 
CR, Keap1 WT and KD and miRNA expression was quantified from pooled 
RNA samples from WT CR and KEap-1KD CR mice by RT2-PCR using 
Mouse Genome V2.0 miRNA array from SABiosceinces as per 
manufacturer’s insturtions.  Data analysis was performed with the web-
based software package for the miRNA PCR array system. 
(http://www.sabiosciences.com/pcr/arrayanalysis.php).  Data is presented 
as fold increase or decrease in miRNA expression of Keap-1KD CR pooled 
samples over the Keap-1 WT CR poled sample. 
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